

Supporting Information

Metal-free photocleavage of C(non-acyl)-S bond of thioesters for regioselective pyridylthioesterification of styrenes

Qi Wu,^a You-Hui Zhao,^a Lu-Lu Chai,^a Hai-Yan Li^b and Hong-Xi Li^{a,*}

^a College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China.

^b Analysis and Testing Centre, Soochow University, Suzhou 215123, China.

Email: lihx@suda.edu.cn


Table of Contents

General Information	S3
Synthesis of S-2-Pyridyl Thioesters 1a-1r, 1t^{S1-S7}	S3
Synthesis of S-2-Pyridyl Thioester 1s^{S2}	S3
Synthesis of 2s-2v^{S8}	S4
Gram Scale Reaction	S4
X-Ray Data Collection and Structure Determination.....	S4
Table S1. Crystal Data and Structure Refinement for 3aa and 3ac.....	S6
Fig. S1. (a) The reaction set-up with 20 W blue LEDs. (b) The gram scale reaction set-up with 20 W blue LEDs.....	S7
Fig. S2. The diastereomeric ratio of 3aq and 3aw.....	S7
Fig. S3. Molecular structures of 3aa and 3ac with 30% thermal probability ellipsoids. All H atoms are omitted for clarity.....	S8
Fig. S4. (a) UV-vis absorption spectra of each mixture for 1a and HNEt ₂ (1a + HNEt ₂ = 4×10 ⁻⁴ mol·L ⁻¹) in DMSO. (b) Job's plots of the EDA complex in DMSO	S8
Fig. S5. Cyclic voltammograms of 1a (a), HNEt ₂ (b), the mixture of 1a with HNEt ₂ (c) and 3aa (d) using (n-Bu) ₄ NPF ₆ as the electrolyte (0.05 M) in DMF at 100 mV/s scan rate.....	S9
Fig. S6. ¹ H NMR spectra showing different ratios of 1b (0.08 mmol) : 2a in DMSO-d ₆ . (a) Full ¹ H NMR spectra. (b) Selected region of the ¹ H NMR spectral window showing diagnostic signals for 1b.....	S10
Fig. S7. ¹ H NMR spectra showing different ratios of 2a (0.08 mmol) : 1b in DMSO-d ₆ . (a) Full ¹ H NMR spectra. (b) Selected region of the ¹ H NMR spectral window showing diagnostic signals for 2a	S11
Fig. S8. ¹ H NMR spectra showing different ratios of 1b (0.10 mmol) : HNEt ₂ in DMSO-d ₆ . (a) Full ¹ H NMR spectra. (b) Selected region of the ¹ H NMR spectral window showing diagnostic signals for 1b.....	S12
Fig. S9. ¹ H NMR spectra showing different ratios of EDA (0.10 mmol 1b, 0.12 mmol HNEt ₂) : 2a in DMSO-d ₆ . (a) Full ¹ H NMR spectra. (b) Selected region of the ¹ H NMR spectral window showing diagnostic signals for EDA.....	S13
Fig. S10. The absorption spectrum of EDA (1a + HNEt ₂) and the emission spectra of different lights.....	S14
Fig. S11. Profile of the reaction with the light off/on over time	S14
Mechanistic Studies.....	S15
NMR Data of Unknown Substrates and Products	S19
References.....	S47
NMR Spectra.....	S48

General Information


Thiopyridyl esters were synthesized by adapting the reported procedures.^{S1,S2} All reagents were used as purchased without further purification. All solvents were obtained from commercial sources and were purified according to standard procedures. Column chromatography was performed on silica gel. ¹H, ¹³C and ¹⁹F NMR spectra were recorded at ambient temperature on a Varian UNITY plus-400 spectrometer. UV-vis absorption spectra were obtained on a Shimadzu UV-2600 Spectrophotometer. Photoluminescence spectra were measured on a Hitachi F2500 apparatus. High-performance liquid chromatography (HPLC) was conducted on a LC-20AT with MeOH and H₂O as the mobile phase. High resolution mass spectra (HRMS) were obtained with a MICRO TOF-Q III. Infrared (IR) spectra were recorded on a Varian 1000 spectrometer using KBr disks (4000-400 cm⁻¹).

Synthesis of S-2-Pyridyl Thioesters 1a-1r, 1t^{S1-S7}



To a solution of pyridine-2-thiol (0.333 g, 3.0 mmol, 1.0 equiv) in CH₂Cl₂ (5 mL) was added acyl chloride (3.6 mmol, 1.2 equiv). After the reaction mixture was stirred at room temperature for 1 h, saturated aqueous NaHCO₃ (10 mL) was added. The mixture was extracted with CH₂Cl₂ (10 mL × 3). The organic layers were combined, dried over Na₂SO₄, and concentrated under reduced pressure to afford a yellow oil. The oil was dissolved in a minimum volume of ethyl acetate and precipitated with petroleum ether. The product was collected by filtration. Compounds **1a-1c**,^{S3} **1d**,^{S4} **1f**,^{S2} **1g-1h**,^{S3} **1i**,^{S5} **1l-1n**,^{S5} **1o**^{S6} and **1p**^{S7} were characterized by comparing their ¹H NMR spectral data with those reported in the literature. New compounds **1e**, **1j**, **1k**, **1q**, **1r**, **1t** were characterized by NMR, IR, MS.

Synthesis of S-2-Pyridyl Thioester 1s^{S2}



To a solution of 2-thiopyridine (0.66 g, 6.0 mmol, 1.5 equiv) and (R)-2-(4-isobutylphenyl)propanoic acid (0.82g, 4.0 mmol, 1.0 equiv) in THF (20 mL) was added 4-dimethylaminopyridine (DMAP, 25 mg, 0.2 mmol, 0.05 equiv.) and dicyclohexylcarbodiimide

(DCC, 1.24 g, 6.0 mmol, 1.5 equiv.) under argon atmosphere. After stirring for 10 h at room temperature, the insoluble dicyclohexylurea was filtered off. The filtrate was concentrated in vacuo. A crude product was purified by column chromatography. Compound **1s** was characterized by comparing its ¹H NMR spectral data with the reported in the literature.^{S2}

Synthesis of **2s-2v**^{S8}

To a DMF (5 mL) solution of carboxylic acid (1 mmol, 1.0 equiv) was added K₂CO₃ (0.207 g, 1.5 mmol, 1.5 equiv), KI (0.249 g, 1.5 mmol, 1.5 equiv), and 4-vinylbenzyl chloride (0.168 g, 1.1 mmol, 1.1 equiv). The reaction mixture was stirred for 12 h at room temperature. The mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layer was collected, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel using petroleum ether (PE) and ethyl acetate (EA) as eluent. Compound **2s**, **2t** was characterized by comparing its ¹H NMR spectral data with the reported in the literature.^{S8} New compounds **2u**, **2v** were characterized by NMR, IR, MS.

Gram Scale Reaction

S-(pyridin-2-yl) benzothioate (1.08 g, 5 mmol, 1.0 equiv), styrene (1.56 g, 15 mmol, 3.0 equiv), and HNEt₂ (0.366 g, 5 mmol, 1.0 equiv) were weighed into a dried 100 mL flask and degassed, anhydrous DMSO (50 mL) was added. The reaction was stirred under a nitrogen atmosphere and irradiated by 20 W blue LEDs for 24 h through cooling with a fan. Next, 100 mL of water was added, and the mixture was extracted three times with ethyl acetate (3 × 40 mL). The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The pure product was obtained by flash column chromatography on silica gel using petroleum ether and ethyl acetate as the eluent: 0.91 g, 57%.

X-Ray Data Collection and Structure Determination

The crystal data of **3aa** and **3ac** were collected on a Rigaku Mercury CCD X-ray diffractometer (3 kV, sealed tube) by using graphite monochromated Mo-K α ($\lambda = 0.71073 \text{ \AA}$), Agilent Xcalibur diffractometer (for **3aa**) or Bruker APEX-II CCD (for **3ac**) using an X-ray source Mo K α ($\lambda = 0.71073 \text{ \AA}$). Single crystals of **3aa** (CCDC 2133458) and **3ac** (CCDC 2133459) were mounted on glass fibers with grease at room temperature (**3ac**) or cooled in a liquid nitrogen stream at 213 K

(3aa). The collected data were reduced by using the program CrystalClear (Rigaku and MSC, Ver. 1.3, 2001), Bruker APEX2 or CrysAlisPro, Agilent Technologies (CrysAlis171 .NET, Version 1.171.36.28) and an absorption correction (multi-scan) was applied. The reflection data were also corrected for Lorentz and polarization effects. The crystal structures of **3aa** and **3ac** were solved by direct methods and refined on F2 by full-matrix least-squares methods with the SHELXTL-2014/7 program.^[S9] All non-H atoms were refined anisotropically. Pertinent crystal data and collection and refinement parameters for **3aa** and **3ac** are summarized in Table S1.

Table S1. Crystal Data and Structure Refinement for 3aa and 3ac

Empirical formula	C ₂₀ H ₁₇ NOS	C ₄₈ H ₅₀ N ₂ O ₂ S ₂
Formula weight	319.4	751.02
Temperature/K	213	293
Crystal system	monoclinic	monoclinic
Space group (number)	<i>P</i> 2 ₁ /c	<i>P</i> 2 ₁ /n
<i>a</i> /Å	9.9510(10)	10.4692(9)
<i>b</i> /Å	17.6043(12)	20.4742(17)
<i>c</i> /Å	10.2940(9)	19.5881(18)
$\alpha/^\circ$	90	
$\beta/^\circ$	111.625(11)	97.740(3)
$\gamma/^\circ$	90	
<i>V</i> /Å ³	1676.4(3)	4160.4(6)
<i>Z</i>	4	4
$\rho_{\text{calc}}/\text{g cm}^{-3}$	1.266	1.199
μ/mm^{-1}	1.731	0.168
<i>F</i> (000)	672	1600
<i>R</i> ₁ ^a	0.0760	0.0954
w <i>R</i> ₂ ^b	0.2123	0.2671
GOF ^c	1.108	1.125

^[a] $R = \sum |F_o| - |F_c| / \sum |F_o|$ ^[b] $R_w = \{\sum w(|F_o| - |F_c|)^2 / \sum w|F_o|^2\}\}^{1/2}$ ^[c]GOF = $\{\sum w(|F_o| - |F_c|)^2 / (M-N)\}\}^{1/2}$, where

M is the number of reflections and *N* is the number of parameters.




Fig. S1. (a) The reaction set-up with 20 W blue LEDs. (b) The gram scale reaction set-up with 20 W blue LEDs.




Fig. S2. The diastereomeric ratio of **3aq** and **3aw**.




Fig. S3. Molecular structures of **3aa** and **3ac** with 30% thermal probability ellipsoids. All H atoms are omitted for clarity.




Fig. S4. (a) UV-vis absorption spectra of each mixture for **1a** and HNEt₂ (**1a** + HNEt₂ = 4×10^{-4} mol L⁻¹) in DMSO. (b) Job's plots of the EDA complex in DMSO.





Fig. S5. Cyclic voltammograms of **1a** (a), HNEt₂ (b), the mixture of **1a** with HNEt₂ (c) and **3aa** (d) using (n-Bu)₄NPF₆ as the electrolyte (0.05 M) in DMF at 100 mV/s scan rate. Working electrode: glassy carbon electrode tip (3 mm diameter); Counter electrode: platinum wire; Reference electrode: Saturated Calomel Electrode (SCE).

(a)



(b)





Fig. S6. ¹H NMR spectra showing different ratios of **1b** (0.08 mmol) : **2a** in DMSO-d₆. (a) Full ¹H NMR spectra. (b) Selected region of the ¹H NMR spectral window showing diagnostic signals for **1b**.

(a)



(b)





Fig. S7. ¹H NMR spectra showing different ratios of **2a** (0.08 mmol) : **1b** in DMSO-d₆. (a) Full ¹H NMR spectra. (b) Selected region of the ¹H NMR spectral window showing diagnostic signals for **2a**.

(a)



(b)




Fig. S8. ^1H NMR spectra showing different ratios of **1b** (0.10 mmol) : HNEt₂ in DMSO-d₆. (a) Full ^1H NMR spectra. (b) Selected region of the ^1H NMR spectral window showing diagnostic signals for **1b**.




Fig. S9. ^1H NMR spectra showing different ratios of EDA (0.10 mmol **1b**, 0.12 mmol HNEt_2) : **2a** in DMSO-d_6 . (a) Full ^1H NMR spectra. (b) Selected region of the ^1H NMR spectral window showing diagnostic signals for EDA.




Fig. S10. The absorption spectrum of EDA (**1a** + HNEt₂) and the emission spectra of different lights.




Fig. S11. Profile of the reaction with the light off/on over time.

Mechanistic Studies





Fig. S12. Mass spectroscopy (MS) of [2-(1-phenyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)ethyl)pyridine



A 10 mL test tube was charged with styrene (0.6 mmol, 3.0 equiv), *S*-(pyridin-2-yl)benzothioate (0.2 mmol, 1.0 equiv), 4-methylbenzothioic *S*-acid (0.2 mmol, 1.0 equiv), K₃PO₄ (0.04 mmol, 0.2 equiv), HNEt₂ (0.2 mmol, 1.0 equiv) and dried DMSO (2 mL) under a nitrogen atmosphere. The reaction mixture was stirred and irradiated with 20 W blue LEDs for 6 h through cooling with a fan. Next, 3 mL of water was added, and the mixture was extracted three times with EA (3 × 3 mL). The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The pure product was obtained by flash column chromatography on silica gel using PE and EA as an eluent. The product was a mixture of **3aa** and **3ba** found by ¹H NMR (Figure S12).





Fig. S13. ¹H NMR spectrum of the mixture of **3aa** and **3ba**.



A 10 mL test tube was charged with styrene (0.6 mmol, 3.0 equiv), *S*-(pyridin-2-yl)benzothioate (0.1 mmol, 0.5 equiv), *S*-(6-methylpyridin-2-yl)4-methylbenzothioate (0.1 mmol, 0.5 equiv), HNEt₂ (0.2 mmol, 1.0 equiv) and dried DMSO (2 mL) under a nitrogen atmosphere. The reaction mixture was stirred and irradiated with 20 W blue LEDs for 6 h through cooling with a fan. Next, 3 mL of water was added, and the mixture was extracted three times with EA (3×3 mL). The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The pure product was obtained by flash column chromatography on silica gel using PE and EA as an eluent. The product was a mixture of **3aa**, **3ba**, **3qa** and **3ta** found by ¹H NMR (Figure S13 and Figure S14).




Fig. S14. ¹H NMR spectrum of the mixture of **3aa** and **3ba**.





Fig. S15. ^1H NMR spectrum of the mixture of **3qa** and **3ta**.

NMR Data of Unknown Substrates and Products

S-(pyridin-2-yl) 4-fluorobenzothioate (**1e**)



Following the General Procedure A with the corresponding 4-fluorobenzoyl chloride (3.6 mmol) and pyridine-2-thiol (3.0 mmol). The crude product was recrystallized by PE, to yield the white solid **1e** (559 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, *J* = 4.5 Hz, 1H), 8.11–7.99 (m, 2H), 7.79 (td, *J* = 7.7, 1.7 Hz, 1H), 7.72 (d, *J* = 7.8 Hz, 1H), 7.37–7.31 (m, 1H), 7.17 (t, *J* = 8.6 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 187.9, 166.2 (d, ¹J_{C-F} = 256.1 Hz), 151.0, 150.6, 137.3, 132.9 (d, ⁴J_{C-F} = 3.0 Hz), 130.9, 130.2 (d, ³J_{C-F} = 9.5 Hz), 123.8, 116.1 (d, ²J_{C-F} = 22.1 Hz).

¹⁹F NMR (377 MHz, CDCl₃) δ -103.58.

IR (KBr disc, cm⁻¹): 3059, 2350, 1671, 1594, 1572, 1499, 1452, 1420, 1408, 1294, 1200, 1151, 1118, 1097, 1080, 902, 839, 723, 476, 457, 442, 426, 414, 405.

m.p. 71.1–73.8 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₂H₉FNOS⁺ 234.0383; Found 234.0380.

S-(pyridin-2-yl) 3-fluorobenzothioate (**1j**)



Following the General Procedure A with the corresponding 3-fluorobenzoyl chloride (3.6 mmol) and pyridine-2-thiol (3.0 mmol). The crude product was recrystallized by PE, to yield the white solid **1j** (454 mg, 65%).

¹H NMR (400 MHz, CDCl₃) δ 8.73–8.64 (m, 1H), 7.86–7.76 (m, 2H), 7.70 (ddd, *J* = 9.1, 6.6, 5.0 Hz, 2H), 7.48 (td, *J* = 8.0, 5.5 Hz, 1H), 7.38–7.28 (m, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 187.2 (d, ⁴J_{C-F} = 2.7 Hz), 161.7 (d, ¹J_{C-F} = 249.0 Hz), 149.8, 149.6, 137.5 (d, ³J_{C-F} = 6.6 Hz), 136.3, 129.5 (d, ³J_{C-F} = 7.9 Hz), 129.5, 122.8, 122.3 (d, ⁴J_{C-F} = 3.3 Hz), 119.9 (d, ²J_{C-F} = 21.6 Hz), 113.4 (d, ²J_{C-F} = 23.2 Hz).


¹⁹F NMR (377 MHz, CDCl₃) δ -111.08.

IR (KBr disc, cm⁻¹): 3086, 3067, 3044, 2349, 1974, 1789, 1676, 1609, 1561, 1482, 1420, 1284, 1278, 1243, 1170, 1110, 1077, 1044, 984, 897, 795, 777, 742, 724, 693, 617, 573, 432, 413, 404.

m.p.: 39.3–40.1 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₂H₉FNOS⁺ 234.0383; Found 234.0378.

S-(pyridin-2-yl) 3,4-dimethoxybenzothioate (**1k**)



Following the General Procedure A with the corresponding 3,4-dimethoxybenzoyl chloride (3.6 mmol) and pyridine-2-thiol (3.0 mmol). The crude product was recrystallized by PE, to yield the white solid **1k** (742 mg, 90%).

¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, *J* = 4.1 Hz, 1H), 7.83–7.70 (m, 3H), 7.50 (d, *J* = 2.0 Hz, 1H), 7.36–7.30 (m, 1H), 6.94 (d, *J* = 8.5 Hz, 1H), 3.97 (s, 3H), 3.94 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 187.9, 153.9, 151.7, 150.5, 149.1, 137.1, 130.9, 129.5, 123.5, 122.3, 110.4, 109.8, 56.2, 56.1.

IR (KBr disc, cm⁻¹): 3012, 2955, 2933, 2381, 2350, 2327, 1668, 1592, 1581, 1564, 1515, 1449, 1421, 1346, 1267, 1243, 1146, 1119, 1012, 987, 969, 863, 803, 761, 737, 723, 675, 618, 596, 455, 433, 420, 403.

m.p.: 89.1–90.2 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₄H₁₄NO₃S⁺ 276.0689; Found 276.0688.

***S*-(6-methylpyridin-2-yl) benzothioate (1q)**



Following the General Procedure A with the corresponding benzoyl chloride (0.48 mmol) and 6-methylpyridine-2-thiol (0.4 mmol). The crude product was recrystallized by PE, to yield the white solid **1q** (77.9 mg, 85%).

¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, *J* = 7.2 Hz, 2H), 7.67 (t, *J* = 7.7 Hz, 1H), 7.63–7.57 (m, 1H), 7.54 (d, *J* = 7.8 Hz, 1H), 7.48 (t, *J* = 7.8 Hz, 2H), 7.19 (d, *J* = 7.6 Hz, 1H), 2.60 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 189.6, 159.8, 150.1, 137.4, 136.6, 133.8, 128.8, 128.0, 127.6, 123.4, 24.4.

IR (KBr disc, cm⁻¹): 3060, 1785, 1708, 1676, 1583, 1559, 1443, 1385, 1313, 1206, 1170, 1139, 1039, 992, 894, 863, 776, 707, 683, 645, 616, 547, 482.

m.p.: 87.2–88.4 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₃H₁₂NOS⁺ 230.0634; Found 230.0633.

***S*-(5-bromopyridin-2-yl) benzothioate (1r)**



Following the General Procedure A with the corresponding benzoyl chloride (0.48 mmol) and 5-bromopyridine-2-thiol (0.4 mmol). The crude product was recrystallized by PE, to yield the white solid **1r** (94.1 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ 8.73 (d, *J* = 2.3 Hz, 1H), 8.05–7.97 (m, 2H), 7.91 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.63 (dd, *J* = 7.9, 4.9 Hz, 2H), 7.50 (t, *J* = 7.8 Hz, 2H).


¹³C NMR (101 MHz, CDCl₃) δ 188.7, 151.6, 150.0, 139.8, 136.3, 134.1, 131.7, 128.9, 127.6, 121.3.

IR (KBr disc, cm⁻¹): 3052, 2349, 2330, 2298, 1665, 1593, 1579, 1550, 1439, 1312, 1261, 1231, 1201, 1144, 1130, 1105, 1000, 905, 827, 803, 769, 728, 681, 640, 485, 440, 424.

m.p.: 93.8–95.2 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₂H₉BrNOS⁺ 293.9583; Found 293.9583.

S-(6-methylpyridin-2-yl) 4-methylbenzothioate (**1t**)



Following the General Procedure A with the corresponding 4-methylbenzoyl chloride (0.48 mmol) and 6-methylpyridine-2-thiol (0.4 mmol). The crude product was recrystallized by PE, to yield the white solid **1t** (77.8 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ 7.91 (d, *J* = 7.0 Hz, 2H), 7.66 (td, *J* = 7.7, 1.3 Hz, 1H), 7.54 (d, *J* = 7.7 Hz, 1H), 7.27 (d, *J* = 8.6 Hz, 2H), 7.18 (d, *J* = 7.7 Hz, 1H), 2.60 (s, 3H), 2.42 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 189.1, 159.7, 150.4, 144.8, 137.3, 134.1, 129.5, 128.0, 127.7, 123.3, 24.4, 21.7.

IR (KBr disc, cm⁻¹): 3327, 3118, 3035, 2920, 2857, 2726, 2011, 1783, 1669, 1605, 1573, 1441, 1409, 1307, 1249, 1205, 1167, 1137, 1040, 999, 891, 854, 812, 784, 715, 681, 632.

m.p.: 96.4–98.2 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₄H₁₄NOS⁺ 244.0791; Found 244.0794.

4-vinylbenzyl (*R*)-2-(4-isobutylphenyl)propanoate (**2u**)



Following the General Procedure C with the corresponding (*R*)-2-(4-isobutylphenyl)propanoic acid (1.0 mmol) and 4-vinylbenzyl chloride (1.1 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 100/1) as an eluent, to yield the transparent oil **2u** (274 mg, 85%).


¹H NMR (400 MHz, CDCl₃) δ 7.35–7.29 (m, 2H), 7.18 (dd, *J* = 9.8, 8.2 Hz, 4H), 7.08 (d, *J* = 8.1 Hz, 2H), 6.68 (dd, *J* = 17.6, 10.9 Hz, 1H), 5.72 (dd, *J* = 17.6, 0.7 Hz, 1H), 5.23 (dd, *J* = 10.9, 0.7 Hz, 1H), 5.08 (d, *J* = 1.3 Hz, 2H), 3.74 (q, *J* = 7.2 Hz, 1H), 2.44 (d, *J* = 7.2 Hz, 2H), 1.84 (dp, *J* = 13.6, 6.8 Hz, 1H), 1.50 (d, *J* = 7.2 Hz, 3H), 0.90 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (101 MHz, CDCl₃) δ 174.5, 140.6, 137.6, 137.4, 136.4, 135.7, 129.4, 128.1, 127.3, 126.3, 114.2, 66.1, 45.2, 45.1, 30.2, 22.4, 18.4.

IR (KBr disc, cm⁻¹): 2954, 2868, 2350, 1733, 1630, 1514, 1458, 1421, 1407, 1378, 1319, 1234, 1199, 1156, 1117, 1092, 1073, 1055, 1032, 989, 961, 942, 909, 847, 826, 800, 477, 464, 456, 432, 416.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₂H₂₇O₂⁺ 323.2006; Found 323.1998.

4-vinylbenzyl (S)-2-(6-methoxynaphthalen-2-yl)propanoate (2v)



Following the General Procedure C with the corresponding (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid (1.0 mmol) and 4-vinylbenzyl chloride (1.1 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 100/1) as an eluent, to yield the transparent oil **2v** (242 mg, 70%).


¹H NMR (400 MHz, CDCl₃) δ 7.67 (t, *J* = 9.2 Hz, 2H), 7.63 (s, 1H), 7.39 (dd, *J* = 8.4, 1.7 Hz, 1H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.19 (d, *J* = 8.1 Hz, 2H), 7.16–7.08 (m, 2H), 6.68 (dd, *J* = 17.6, 10.9 Hz, 1H), 5.72 (d, *J* = 17.6 Hz, 1H), 5.24 (d, *J* = 10.9 Hz, 1H), 5.09 (q, *J* = 12.5 Hz, 2H), 3.93–3.86 (m, 4H), 1.58 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 174.5, 157.6, 137.4, 136.4, 135.5, 135.5, 133.7, 129.3, 128.9, 128.3, 127.2, 126.3, 126.0, 119.0, 114.3, 105.6, 66.3, 55.3, 45.5, 18.5.

IR (KBr disc, cm⁻¹): 2991, 2971, 2929, 2853, 2350, 1741, 1629, 1603, 1513, 1376, 1329, 1266, 1177, 1149, 1091, 1078, 1027, 917, 856, 824, 793, 748, 728, 684, 478, 464, 457, 438, 419, 404.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₃H₂₃O₃⁺ 347.1642; Found 347.1645.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) benzothioate (3aa)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3aa** (58.7 mg, 92%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.92 (dd, *J* = 8.3, 1.1 Hz, 2H), 7.60–7.50 (m, 2H), 7.43–7.35 (m, 4H), 7.30 (t, *J* = 7.5 Hz, 2H), 7.25–7.19 (m, 1H), 7.14 (ddd, *J* = 9.2, 5.9, 4.6 Hz, 2H), 4.41 (dd, *J* = 8.8, 6.8 Hz, 1H), 3.98 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.82 (dd, *J* = 13.3, 6.7 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 192.1, 161.5, 149.3, 142.5, 137.1, 136.5, 133.3, 128.7, 128.5, 128.1, 127.2, 127.0, 123.8, 121.8, 53.0, 33.7.

IR (KBr disc, cm⁻¹): 2960, 2923, 2360, 1655, 1588, 1571, 1492, 1471, 1432, 1201, 1173, 1159, 1147, 1077, 999, 912, 836, 800, 774, 758, 686, 496, 477, 469, 437, 431, 424, 417, 404.

m.p.: 85.2–86.5 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₈NOS⁺ 320.1104; Found 320.1090.

S-(2-(pyridin-2-yl)-2-(*p*-tolyl)ethyl) benzothioate (**3ab**)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-methyl-4-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ab** (63.3 mg, 95%).

¹H NMR (400 MHz, CDCl₃) δ 8.61 (dd, *J* = 4.9, 0.8 Hz, 1H), 7.92 (dd, *J* = 8.3, 1.2 Hz, 2H), 7.55 (td, *J* = 7.7, 1.9 Hz, 1H), 7.52 (ddd, *J* = 7.0, 2.5, 1.3 Hz, 1H), 7.39 (t, *J* = 7.7 Hz, 2H), 7.26 (d, *J* = 8.1 Hz, 2H), 7.15 (d, *J* = 7.9 Hz, 1H), 7.14–7.09 (m, 3H), 4.38 (dd, *J* = 8.7, 7.0 Hz, 1H), 3.96 (dd, *J* = 13.3, 8.8 Hz, 1H), 3.80 (dd, *J* = 13.3, 6.9 Hz, 1H), 2.30 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 192.1, 161.7, 149.2, 139.5, 137.1, 136.6, 136.5, 133.3, 129.4, 128.5, 128.0, 127.3, 123.7, 121.7, 52.6, 33.8, 21.1.

IR (KBr disc, cm⁻¹): 3361, 2978, 2904, 2360, 2336, 1655, 1589, 1512, 1431, 1399, 1205, 1049, 906, 882, 818, 748, 721, 687, 610, 527, 490, 452, 420.

m.p.: 63.6–64.1 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₁H₂₀NOS⁺ 334.1260; Found 334.1248.

S-(2-(4-(*tert*-butyl)phenyl)-2-(pyridin-2-yl)ethyl) benzothioate (**3ac**)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-(*tert*-butyl)-4-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ac** (72.0 mg, 96%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 4.9, 0.9 Hz, 1H), 7.92 (dd, *J* = 8.3, 1.1 Hz, 2H), 7.56 (td, *J* = 7.7, 1.9 Hz, 1H), 7.53 (t, *J* = 8.0 Hz, 1H), 7.40 (t, *J* = 7.7 Hz, 2H), 7.35–7.27 (m, 4H), 7.17 (d, *J* = 7.8 Hz, 1H), 7.13 (ddd, *J* = 7.5, 4.9, 1.0 Hz, 1H), 4.38 (dd, *J* = 9.2, 6.4 Hz, 1H), 3.96 (dd, *J* = 13.3, 9.2 Hz, 1H), 3.81 (dd, *J* = 13.3, 6.4 Hz, 1H), 1.29 (s, 9H).


¹³C NMR (101 MHz, CDCl₃) δ 192.1, 161.7, 149.7, 149.2, 139.4, 137.2, 136.5, 133.2, 128.5, 127.6, 127.2, 125.5, 123.8, 121.7, 52.5, 34.4, 33.8, 31.3.

IR (KBr disc, cm⁻¹): 3056, 2961, 2905, 2869, 2361, 1661, 1586, 1511, 1469, 1413, 1364, 1268, 1205, 1175, 1108, 1050, 909, 831, 753, 689, 648, 615, 569, 441, 420.

m.p.: 95.6–96.9 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₄H₂₆NOS⁺ 376.1730; Found 376.1746.

***S*-(2-(4-methoxyphenyl)-2-(pyridin-2-yl)ethyl) benzothioate (3ad)**



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-methoxy-4-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3ad** (67.0 mg, 96%).


¹H NMR (400 MHz, CDCl₃) δ 8.61 (ddd, *J* = 4.8, 1.6, 0.7 Hz, 1H), 7.91 (dd, *J* = 8.3, 1.2 Hz, 2H), 7.54 (td, *J* = 7.7, 1.9 Hz, 1H), 7.51 (t, *J* = 7.4 Hz, 1H), 7.38 (t, *J* = 7.7 Hz, 2H), 7.32–7.26 (m, 2H), 7.14 (d, *J* = 7.9 Hz, 1H), 7.11 (ddd, *J* = 7.5, 5.0, 1.1 Hz, 1H), 6.87–6.81 (m, 2H), 4.36 (dd, *J* = 8.6, 7.0 Hz, 1H), 3.95 (dd, *J* = 13.3, 8.7 Hz, 1H), 3.78 (dd, *J* = 13.3, 6.9 Hz, 1H), 3.75 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 192.1, 161.8, 158.6, 149.2, 137.2, 136.5, 134.7, 133.3, 129.1, 128.5, 127.2, 123.6, 121.7, 114.0, 55.2, 52.2, 33.9.

IR (KBr disc, cm⁻¹): 3060, 3005, 2933, 2835, 2350, 1656, 1609, 1588, 1510, 1471, 1448, 1433, 1303, 1247, 1205, 1175, 1035, 995, 908, 830, 796, 773, 748, 688, 648, 614, 568, 537, 464, 457, 432, 413, 403.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₁H₂₀NO₂S⁺ 350.1209; Found 350.1182.

***S*-(2-(4-fluorophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (3ae)**



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-fluoro-4-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ae** (62.0 mg, 92%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 4.5 Hz, 1H), 7.91 (d, *J* = 7.4 Hz, 2H), 7.57 (td, *J* = 7.7, 1.9 Hz, 1H), 7.53 (t, *J* = 8.2 Hz, 1H), 7.40 (t, *J* = 7.8 Hz, 2H), 7.35 (dd, *J* = 8.6, 5.4 Hz, 2H), 7.14 (t, *J* = 6.1 Hz, 2H), 6.98 (t, *J* = 8.7 Hz, 2H), 4.39 (dd, *J* = 8.5, 7.1 Hz, 1H), 3.94 (dd, *J* = 13.3, 8.8 Hz, 1H), 3.78 (dd, *J* = 13.3, 6.8 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 192.0, 161.9 (d, ¹J_{C-F} = 245.5 Hz), 161.2, 149.4, 138.2 (d, ⁴J_{C-F} = 3.0 Hz), 137.0, 136.6, 133.4, 129.7 (d, ³J_{C-F} = 8.0 Hz), 128.6, 127.2, 123.7, 121.9, 115.4 (d, ²J_{C-F} = 21.3 Hz), 52.2, 33.9.


¹⁹F NMR (376 MHz, CDCl₃) δ -115.77.

IR (KBr disc, cm⁻¹): 3846, 2924, 2355, 1659, 1590, 1506, 1462, 1431, 1302, 1213, 1163, 1091, 913, 833, 759, 687, 645, 537.

m.p.: 73.5–74.8 °C.

QTOF-MS: *m/z* [M + Na]⁺ Calcd for C₂₀H₁₆FNNaOS⁺ 360.0829; Found 360.0809.

S-(2-(4-chlorophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (3af)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-chloro-4-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3af** (61.4 mg, 87%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 5.2, 1.8 Hz, 1H), 7.91 (dd, *J* = 7.3, 1.2 Hz, 2H), 7.57 (td, *J* = 7.7, 1.9 Hz, 1H), 7.53 (t, *J* = 8.2 Hz, 1H), 7.40 (t, *J* = 7.7 Hz, 2H), 7.29 (dd, *J* = 24.0, 8.6 Hz, 4H), 7.14 (dd, *J* = 7.7, 3.5 Hz, 2H), 4.37 (dd, *J* = 8.4, 7.1 Hz, 1H), 3.93 (dd, *J* = 13.4, 8.7 Hz, 1H), 3.77 (dd, *J* = 13.4, 6.9 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 192.0, 161.0, 149.4, 140.9, 137.0, 136.6, 133.4, 132.9, 129.5, 128.8, 128.6, 127.2, 123.7, 122.0, 52.3, 33.7.

IR (KBr disc, cm⁻¹): 3851, 3738, 3614, 3492, 3059, 2926, 2359, 1656, 1581, 1480, 1434, 1403, 1301, 1203, 1173, 1088, 1006, 911, 824, 756, 684, 644, 530.

m.p.: 71.5–73.0 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇ClNOS⁺ 354.0714; Found 354.0684.

S-(2-(4-bromophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (3ag)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-bromo-4-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ag** (63.5 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 5.7, 1.7 Hz, 1H), 7.91 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.57 (td, *J* = 7.7, 1.8 Hz, 1H), 7.53 (t, *J* = 8.2 Hz, 1H), 7.44–7.37 (m, 4H), 7.29–7.24 (m, 2H), 7.15 (td,

J = 3.7, 1.1 Hz, 1H), 7.14 (d, *J* = 7.7 Hz, 1H), 4.36 (dd, *J* = 8.5, 7.0 Hz, 1H), 3.93 (dd, *J* = 13.4, 8.7 Hz, 1H), 3.77 (dd, *J* = 13.4, 6.9 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 192.0, 160.9, 149.4, 141.4, 137.0, 136.6, 133.4, 131.7, 129.9, 128.6, 127.2, 123.7, 122.0, 121.0, 52.4, 33.6.

IR (KBr disc, cm⁻¹): 3060, 3013, 2930, 1659, 1583, 1478, 1437, 1402, 1301, 1205, 1068, 1003, 912, 823, 756, 684, 644, 614, 528, 487.

m.p.: 70.0–70.7 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇BrNOS⁺ 398.0209; Found 398.0201.

S-(2-(pyridin-2-yl)-2-(4-(trifluoromethyl)phenyl)ethyl) benzothioate (3ah)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-(trifluoromethyl)-4-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the pale yellow oil **3ah** (72.2 mg, 93%).

¹H NMR (400 MHz, CDCl₃) δ 8.64 (dd, *J* = 5.2, 1.5 Hz, 1H), 7.92 (d, *J* = 7.8 Hz, 2H), 7.63–7.49 (m, 6H), 7.41 (t, *J* = 7.7 Hz, 2H), 7.17 (d, *J* = 7.7 Hz, 1H), 7.16 (d, *J* = 7.4 Hz, 1H), 4.50–4.42 (m, 1H), 3.97 (dd, *J* = 13.4, 8.7 Hz, 1H), 3.81 (dd, *J* = 13.4, 6.8 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 191.9, 160.5, 149.5, 146.3, 136.9, 136.7, 133.5, 129.2 (q, ²J_{C-F} = 32.4 Hz), 128.6, 128.5, 127.2, 125.6 (q, ³J_{C-F} = 3.8 Hz), 124.2 (q, ¹J_{C-F} = 272.0 Hz), 123.8, 122.2, 52.8, 33.6.

¹⁹F NMR (376 MHz, CDCl₃) δ -62.43.

IR (KBr disc, cm⁻¹): 3745, 3672, 2969, 2929, 2361, 1661, 1618, 1586, 1417, 1325, 1207, 1166, 1123, 1068, 1019, 909, 838, 772, 750, 689, 649.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₁H₁₇F₃NOS⁺ 388.0977; Found 388.0986.

4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)phenyl acetate (3ai)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 4-vinylphenyl acetate (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ai** (55.8 mg, 74%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 4.4 Hz, 1H), 7.91 (dd, *J* = 7.2, 1.4 Hz, 2H), 7.56 (td, *J* = 7.6, 1.7 Hz, 1H), 7.53 (t, *J* = 8.2 Hz, 1H), 7.44–7.35 (m, 4H), 7.18–7.10 (m, 2H), 7.05–6.99 (m,

2H), 4.40 (dd, J = 9.0, 6.6 Hz, 1H), 3.94 (dt, J = 14.0, 7.0 Hz, 1H), 3.79 (dd, J = 13.3, 6.5 Hz, 1H), 2.27 (s, 3H).


^{13}C NMR (101 MHz, CDCl_3) δ 192.0, 169.5, 161.1, 149.6, 149.3, 140.0, 137.0, 136.6, 133.3, 129.1, 128.6, 127.2, 123.9, 121.9, 121.6, 52.4, 33.8, 21.2.

IR (KBr disc, cm^{-1}): 3005, 2928, 1982, 1924, 1748, 1655, 1586, 1505, 1467, 1431, 1366, 1309, 1281, 1200, 1171, 1103, 1046, 1017, 906, 874, 837, 812, 789, 754, 717, 685, 640.

m.p.: 91.0–92.5 °C.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{22}\text{H}_{20}\text{NO}_3\text{S}^+$ 378.1158; Found 378.1155.

S-(2-(pyridin-2-yl)-2-(*m*-tolyl)ethyl) benzothioate (3aj)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-methyl-3-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3aj** (60.6 mg, 91%).

^1H NMR (400 MHz, CDCl_3) δ 8.61 (dd, J = 4.8, 0.8 Hz, 1H), 7.91 (dd, J = 7.2, 1.4 Hz, 2H), 7.54 (td, J = 7.7, 1.8 Hz, 1H), 7.51 (t, J = 7.4 Hz, 1H), 7.38 (dd, J = 10.7, 4.8 Hz, 2H), 7.22–7.14 (m, 4H), 7.12 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.03 (d, J = 7.1 Hz, 1H), 4.37 (dd, J = 9.0, 6.7 Hz, 1H), 3.97 (dd, J = 13.3, 9.0 Hz, 1H), 3.81 (dd, J = 13.3, 6.6 Hz, 1H), 2.31 (s, 3H).


^{13}C NMR (101 MHz, CDCl_3) δ 192.1, 161.6, 149.2, 142.4, 138.3, 137.1, 136.5, 133.3, 128.8, 128.6, 127.84, 127.26, 125.08, 123.76, 121.77, 52.94, 33.70, 21.51.

IR (KBr disc, cm^{-1}): 3869, 3856, 3829, 3744, 3054, 3015, 2924, 2358, 1656, 1579, 1462, 1432, 1203, 1172, 1088, 1042, 908, 758, 685, 642.

m.p.: 55.1–56.2 °C.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{21}\text{H}_{20}\text{NOS}^+$ 334.1260; Found 334.1239.

S-(2-(3-chlorophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (3ak)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-chloro-3-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3ak** (48.7 mg, 69%).


¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 5.4, 1.8 Hz, 1H), 7.91 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.57 (td, *J* = 7.7, 1.8 Hz, 1H), 7.52 (ddd, *J* = 7.0, 4.1, 1.3 Hz, 1H), 7.43–7.36 (m, 3H), 7.28 (dt, *J* = 7.3, 1.6 Hz, 1H), 7.23 (t, *J* = 7.6 Hz, 1H), 7.20 (t, *J* = 1.8 Hz, 1H), 7.17–7.12 (m, 2H), 4.37 (dd, *J* = 8.8, 6.7 Hz, 1H), 3.94 (dd, *J* = 13.4, 8.9 Hz, 1H), 3.78 (dd, *J* = 13.3, 6.7 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 191.9, 160.7, 149.5, 144.4, 137.0, 136.6, 134.4, 133.4, 129.9, 128.6, 128.3, 127.3, 126.4, 123.8, 122.1, 52.6, 33.7.

IR (KBr disc, cm⁻¹): 3594, 2975, 2361, 1924, 1661, 1382, 1048, 881, 690.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇ClNOS⁺ 354.0714; Found 354.0693.

S-(2-(2-chlorophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (3al)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-chloro-3-vinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3al** (59.3 mg, 84%).

¹H NMR (400 MHz, CDCl₃) δ 8.60 (d, *J* = 4.7 Hz, 1H), 7.90 (d, *J* = 7.6 Hz, 2H), 7.55 (d, *J* = 1.6 Hz, 1H), 7.50 (dd, *J* = 16.1, 8.1 Hz, 2H), 7.41–7.33 (m, 3H), 7.20 (t, *J* = 6.9 Hz, 2H), 7.17–7.09 (m, 2H), 5.03 (t, *J* = 7.8 Hz, 1H), 3.99 (dd, *J* = 13.2, 8.3 Hz, 1H), 3.84 (dd, *J* = 13.2, 7.3 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 191.7, 160.6, 149.4, 139.7, 137.1, 136.5, 134.1, 133.3, 129.7, 129.3, 128.5, 128.2, 127.3, 127.1, 124.0, 122.0, 48.1, 32.9.

IR (KBr disc, cm⁻¹): 3061, 2924, 2853, 1958, 1686, 1657, 1614, 1585, 1487, 1449, 1394, 1333, 1287, 1226, 1204, 1173, 1125, 1095, 1053, 1031, 997, 927, 908, 862, 814, 752, 685, 647, 623.

m.p.: 50.1–51.2 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇ClNOS⁺ 354.0714; Found 354.0696.

S-(2-(naphthalen-2-yl)-2-(pyridin-2-yl)ethyl) benzothioate (3am)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 2-vinylnaphthalene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3am** (33.2 mg, 45%).

¹H NMR (400 MHz, CDCl₃) δ 8.65 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.92 (dd, *J* = 8.3, 1.2 Hz, 2H), 7.80 (dd, *J* = 9.9, 5.0 Hz, 4H), 7.56 (td, *J* = 7.7, 1.8 Hz, 1H), 7.52 (ddd, *J* = 7.7, 4.9, 1.0 Hz, 2H), 7.59–

7.49 (m, 3H), 7.48–7.36 (m, 4H), 7.20 (d, J = 7.9 Hz, 1H), 7.14 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 4.58 (dd, J = 8.5, 7.1 Hz, 1H), 4.07 (dd, J = 13.3, 8.7 Hz, 1H), 3.91 (dd, J = 13.3, 6.9 Hz, 1H).


^{13}C NMR (101 MHz, CDCl_3) δ 192.1, 161.4, 149.3, 139.9, 137.1, 136.5, 133.5, 133.3, 132.5, 128.6, 128.4, 127.9, 127.6, 127.3, 126.8, 126.3, 126.1, 125.8, 123.9, 121.9, 53.1, 33.6.

IR (KBr disc, cm^{-1}): 3056, 3006, 2940, 2851, 2361, 1643, 1579, 1568, 1506, 1487, 1471, 1432, 1412, 1204, 1160, 911, 861, 808, 685, 478, 458, 431, 413, 403.

m.p.: 81.0–82.5 °C.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{24}\text{H}_{20}\text{NOS}^+$ 370.1260; Found 370.1235.

S-(2,2-di(pyridin-2-yl)ethyl) benzothioate (3an)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 2-vinylpyridine (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3an** (44.2 mg, 69%).

^1H NMR (400 MHz, CDCl_3) δ 8.59 (dd, J = 4.8, 0.8 Hz, 2H), 7.96–7.86 (m, 2H), 7.60 (td, J = 7.7, 1.8 Hz, 2H), 7.53 (dd, J = 10.5, 4.3 Hz, 1H), 7.39 (t, J = 7.7 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.14 (ddd, J = 7.4, 4.9, 0.8 Hz, 2H), 4.62 (t, J = 7.8 Hz, 1H), 4.01 (d, J = 7.8 Hz, 2H).


^{13}C NMR (101 MHz, CDCl_3) δ 191.8, 160.8, 149.4, 137.1, 136.6, 133.3, 128.5, 127.3, 123.4, 122.0, 55.1, 32.6.

IR (KBr disc, cm^{-1}): 3050, 3035, 3009, 2920, 2850, 2360, 1656, 1583, 1567, 1467, 1448, 1432, 1395, 1201, 1177, 1152, 1096, 1074, 1052, 905, 769, 749, 683, 628, 614, 595, 532, 414, 403.

m.p.: 70.1–71.8 °C.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{19}\text{H}_{17}\text{N}_2\text{OS}^+$ 321.1056; Found 321.1064.

S-(2-phenyl-2-(pyridin-2-yl)propyl) benzothioate (3ao)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and prop-1-en-2-ylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ao** (40.0 mg, 60%).

^1H NMR (400 MHz, CDCl_3) δ 8.61 (d, J = 4.1 Hz, 1H), 7.95–7.88 (m, 2H), 7.55 (td, J = 7.8, 1.8 Hz, 1H), 7.50 (t, J = 7.4 Hz, 1H), 7.38 (t, J = 7.7 Hz, 2H), 7.32–7.24 (m, 5H), 7.23–7.17 (m, 1H), 7.15–7.08 (m, 2H), 4.12 (d, J = 13.2 Hz, 1H), 4.00 (d, J = 13.2 Hz, 1H), 1.84 (s, 3H).


^{13}C NMR (101 MHz, CDCl_3) δ 192.1, 166.1, 148.3, 146.8, 137.3, 136.3, 133.1, 128.5, 128.3, 127.3, 127.1, 126.6, 122.4, 121.4, 49.5, 40.1, 25.4.

IR (KBr disc, cm^{-1}): 3054, 3002, 2974, 2924, 1961, 1652, 1586, 1565, 1493, 1467, 1444, 1427, 1376, 1291, 1261, 1201, 1173, 1156, 1134, 1091, 1064, 1026, 995, 969, 910, 844, 812, 792, 767, 734, 684, 646, 618.

m.p.: 88.6–90.1 °C.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{21}\text{H}_{20}\text{NOS}^+$ 334.1260; Found 334.1250.

S-(2,2-diphenyl-2-(pyridin-2-yl)ethyl) benzothioate (3ap)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and ethene-1,1-diyldibenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ap** (64.8 mg, 82%).

^1H NMR (400 MHz, CDCl_3) δ 8.62 (dd, J = 5.4, 1.8 Hz, 1H), 7.82–7.75 (m, 2H), 7.52 (td, J = 7.7, 1.9 Hz, 1H), 7.44 (t, J = 7.4 Hz, 1H), 7.31 (t, J = 7.7 Hz, 2H), 7.28–7.16 (m, 10H), 7.11 (dd, J = 7.6, 4.0 Hz, 2H), 4.52 (s, 2H).


^{13}C NMR (101 MHz, CDCl_3) δ 192.2, 164.8, 148.5, 145.2, 137.4, 135.9, 132.9, 129.3, 128.4, 128.0, 127.2, 126.8, 124.8, 121.5, 59.8, 39.6.

IR (KBr disc, cm^{-1}): 3055, 3029, 2921, 2849, 1964, 1635, 1586, 1488, 1467, 1444, 1429, 1294, 1262, 1207, 1178, 1153, 1099, 1034, 997, 965, 931, 916, 844, 812, 791, 773, 750, 697, 688, 650, 637, 614.

m.p.: 155.5–156.6 °C.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{26}\text{H}_{22}\text{NOS}^+$ 396.1417; Found 396.1401.

S-(1-phenyl-1-(pyridin-2-yl)propan-2-yl) benzothioate (3aq)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1-propenylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3aq** (49.3 mg, 74%).

^1H NMR (400 MHz, CDCl_3) δ 8.53 (dd, J = 4.8, 0.9 Hz, 1H), 7.85 (dd, J = 8.4, 1.2 Hz, 2H), 7.51 (td, J = 7.7, 1.7 Hz, 1H), 7.48 (dd, J = 7.2, 6.0 Hz, 3H), 7.36 (dd, J = 10.6, 4.8 Hz, 2H), 7.30 (dd, J = 10.3, 4.7 Hz, 2H), 7.25 (d, J = 7.9 Hz, 1H), 7.23–7.17 (m, 1H), 7.04 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 4.80 (dq, J = 10.6, 6.8 Hz, 1H), 4.32 (d, J = 10.6 Hz, 1H), 1.39 (d, J = 6.8 Hz, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 191.6, 161.6, 149.3, 141.2, 137.3, 136.4, 133.1, 128.6, 128.6, 128.5, 127.2, 127.1, 123.0, 121.7, 58.6, 43.2, 21.0.

IR (KBr disc, cm⁻¹): 3284, 3077, 3052, 3023, 2962, 2923, 2864, 1646, 1586, 1490, 1470, 1450, 1432, 1373, 1348, 1312, 1298, 1261, 1206, 1152, 1117, 1070, 1019, 994, 909, 771, 748, 688, 649, 618.

m.p.: 112.7–113.8 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₁H₂₀NOS⁺ 334.1260; Found 334.1261.

***S*-(3-phenyl-2-(pyridin-2-yl)propyl) benzothioate (3ar)**



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and allylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3ar** (37.3 mg, 56%).


¹H NMR (400 MHz, CDCl₃) δ 8.61 (dd, *J* = 4.8, 0.9 Hz, 1H), 7.91 (dd, *J* = 8.3, 1.2 Hz, 2H), 7.54 (ddd, *J* = 8.5, 2.4, 1.1 Hz, 1H), 7.47 (td, *J* = 7.6, 1.8 Hz, 1H), 7.41 (t, *J* = 7.7 Hz, 2H), 7.21–7.09 (m, 4H), 7.02 (d, *J* = 6.7 Hz, 2H), 6.87 (d, *J* = 7.8 Hz, 1H), 3.54 (ddd, *J* = 21.8, 13.2, 7.3 Hz, 2H), 3.35 (tt, *J* = 8.5, 6.2 Hz, 1H), 3.21–3.09 (m, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 191.8, 161.7, 149.5, 139.5, 137.1, 136.1, 133.3, 129.1, 128.6, 128.2, 127.23, 126.1, 124.1, 121.8, 49.4, 41.5, 33.5.

IR (KBr disc, cm⁻¹): 3280, 3022, 2961, 2923, 2361, 1658, 1577, 1572, 1492, 1471, 1432, 1202, 1172, 1161, 1148, 1076, 1012, 910, 836, 800, 774, 758, 688, 496, 477, 469.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₁H₁₉NNaOS⁺ 356.1080; Found 356.1088.

4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)benzyl 2-(*p*-tolyl)acetate (3as)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 4-vinylbenzyl 2-(*p*-tolyl)acetate (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3as** (63.5 mg, 66%).


¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.91 (dd, *J* = 8.2, 1.1 Hz, 2H), 7.60–7.53 (m, 1H), 7.51 (d, *J* = 7.4 Hz, 1H), 7.42–7.34 (m, 4H), 7.25 (d, *J* = 8.2 Hz, 2H), 7.13 (dd, *J* = 18.5, 8.0 Hz, 6H), 5.07 (s, 2H), 4.41 (dd, *J* = 8.8, 6.8 Hz, 1H), 3.96 (dd, *J* = 13.3, 8.8 Hz, 1H), 3.80 (dd, *J* = 13.3, 6.7 Hz, 1H), 3.60 (s, 2H), 2.31 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 192.0, 171.7, 161.2, 149.3, 142.5, 137.1, 136.8, 136.6, 134.6, 133.4, 130.8, 129.3, 129.2, 128.6, 128.5, 128.3, 127.3, 123.8, 121.9, 66.3, 52.7, 40.9, 33.7, 21.1.

IR (KBr disc, cm⁻¹): 3052, 2952, 2924, 1733, 1658, 1616, 1589, 1581, 1569, 1515, 1471, 1448, 1433, 1206, 1146, 909, 773, 750, 688, 648, 616, 442, 414, 403.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₃₀H₂₈NO₃S⁺ 482.1784; Found 482.1784.

4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)benzyl 2-(1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl)acetate (3at)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 4-vinylbenzyl 2-(1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl)acetate (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3at** (72.9 mg, 62%).


¹H NMR (400 MHz, CDCl₃) δ 8.61 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.91 (dd, *J* = 5.2, 3.3 Hz, 2H), 7.70 (d, *J* = 8.1 Hz, 2H), 7.56 (td, *J* = 8.1, 1.8 Hz, 1H), 7.52 (t, *J* = 7.4 Hz, 1H), 7.44–7.36 (m, 4H), 7.28 (d, *J* = 8.2 Hz, 2H), 7.23 (d, *J* = 7.9 Hz, 2H), 7.13 (ddd, *J* = 8.2, 5.9, 4.4 Hz, 2H), 6.66 (d, *J* = 4.0 Hz, 1H), 6.09 (d, *J* = 4.1 Hz, 1H), 5.13 (s, 2H), 4.41 (dd, *J* = 8.7, 6.8 Hz, 1H), 3.96 (dd, *J* = 13.3, 8.8 Hz, 1H), 3.90 (s, 3H), 3.80 (dd, *J* = 13.3, 6.7 Hz, 1H), 3.72 (s, 2H), 2.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 192.0, 185.9, 169.2, 161.2, 149.4, 142.8, 141.9, 137.4, 137.1, 136.6, 134.3, 134.1, 133.4, 131.5, 129.5, 128.7, 128.7, 128.6, 128.4, 127.2, 123.8, 122.3, 121.9, 109.5, 66.9, 52.7, 33.7, 33.2, 32.9, 21.6.

IR (KBr disc, cm⁻¹): 2951, 1736, 1657, 1621, 1605, 1568, 1512, 1481, 1454, 1433, 1407, 1373, 1263, 1204, 1172, 1112, 1043, 995, 979, 882, 834, 773, 748, 688, 648, 617, 415, 404.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₃₆H₃₃N₂O₄S⁺ 589.2156; Found 589.2156.

4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)benzyl (2*R*)-2-(4-isobutylphenyl)propanoate (3au)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 4-vinylbenzyl (2*R*)-2-(4-isobutylphenyl)propanoate (0.6 mmol). The crude product was purified

by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3au** (77.3 mg, 72%).


¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 5.8, 1.5 Hz, 1H), 7.91 (dd, *J* = 8.3, 1.1 Hz, 2H), 7.60–7.50 (m, 2H), 7.40 (dd, *J* = 10.8, 4.7 Hz, 2H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.16 (tt, *J* = 7.5, 3.1 Hz, 6H), 7.07 (dd, *J* = 8.1, 1.9 Hz, 2H), 5.06 (q, *J* = 12.6 Hz, 2H), 4.39 (dd, *J* = 8.7, 6.8 Hz, 1H), 3.95 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.78 (dd, *J* = 13.3, 6.7 Hz, 1H), 3.73 (q, *J* = 7.2 Hz, 1H), 2.44 (d, *J* = 7.2 Hz, 2H), 1.84 (tp, *J* = 13.1, 6.6 Hz, 1H), 1.49 (d, *J* = 7.2 Hz, 3H), 0.89 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (101 MHz, CDCl₃) δ 192.0, 174.6, 161.3, 149.3, 142.3, 140.6, 137.6, 137.1, 136.6, 134.8, 133.3, 129.3, 128.6, 128.2, 128.1, 127.2, 127.2, 123.8, 121.9, 66.0, 52.7, 45.1, 45.0, 33.7, 30.2, 22.4, 18.5.

IR (KBr disc, cm⁻¹): 2954, 2931, 2868, 2350, 1733, 1659, 1589, 1570, 1513, 1448, 1434, 1380, 1205, 1092, 1074, 1021, 1009, 997, 909, 847, 773, 749, 689, 649, 616, 597, 540, 422.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₃₄H₃₆NO₃S⁺ 538.2410; Found 538.2410.

4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)benzyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate (3av)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 4-vinylbenzyl (*S*)-2-(6-methoxynaphthalen-2-yl)propanoate (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3av** (62.8 mg, 56%).


¹H NMR (400 MHz, CDCl₃) δ 8.60 (dd, *J* = 5.6, 1.7 Hz, 1H), 7.90 (dd, *J* = 8.3, 1.2 Hz, 2H), 7.70–7.60 (m, 3H), 7.56–7.47 (m, 2H), 7.41–7.34 (m, 3H), 7.30 (d, *J* = 8.1 Hz, 2H), 7.17 (d, *J* = 8.1 Hz, 2H), 7.14–7.07 (m, 4H), 5.06 (dd, *J* = 28.5, 12.5 Hz, 2H), 4.38 (dd, *J* = 8.8, 6.7 Hz, 1H), 3.98–3.91 (m, 1H), 3.90–3.83 (m, 4H), 3.77 (dd, *J* = 13.3, 6.7 Hz, 1H), 1.57 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 190.9, 173.4, 160.2, 156.6, 148.2, 141.3, 136.0, 135.5, 134.5, 133.7, 132.6, 132.3, 128.2, 127.9, 127.5, 127.2, 127.2, 126.2, 126.1, 125.2, 124.9, 122.7, 120.8, 117.9, 104.6, 65.1, 54.2, 51.6, 44.4, 32.6, 17.5.

IR (KBr disc, cm⁻¹): 3060, 2966, 2936, 1726, 1667, 1651, 1604, 1581, 1513, 1448, 1434, 1393, 1329, 1262, 1197, 1177, 1090, 1028, 909, 854, 818, 746, 684, 458, 443, 420.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₃₅H₃₂NO₄S⁺ 562.2047; Found 562.2047.

***S*-(1-cyclopropyl-2-phenyl-2-(pyridin-2-yl)ethyl) benzothioate (3aw)**



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and (*E*)/(*Z*)-(2-cyclopropylvinyl)benzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3aw** (58.2 mg, 81%).

¹H NMR (400 MHz, CDCl₃) δ 8.56 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.90–7.81 (m, 2H), 7.56 – 7.39 (m, 4H), 7.35 (t, *J* = 7.7 Hz, 2H), 7.25 (dd, *J* = 14.2, 6.9 Hz, 3H), 7.18 (dd, *J* = 8.3, 6.3 Hz, 1H), 7.08–7.02 (m, 1H), 4.64 (d, *J* = 9.4 Hz, 1H), 4.28 (t, *J* = 9.3 Hz, 1H), 1.21–1.08 (m, 1H), 0.44–0.30 (m, 3H), 0.20 (ddd, *J* = 12.6, 6.0, 2.9 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 191.8, 161.6, 149.1, 141.6, 137.3, 136.3, 133.1, 129.0, 128.4, 128.3, 127.3, 126.8, 123.4, 121.7, 58.4, 52.9, 16.6, 8.2, 3.7.

IR (KBr disc, cm⁻¹): 3077, 3021, 2922, 1652, 1581, 1491, 1473, 1455, 1433, 1347, 1206, 1179, 1163, 1076, 1024, 910, 824, 772, 726, 691, 648, 603, 574, 442, 413.

m.p.: 101.3–103.0 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₃H₂₂NOS⁺ 360.1417; Found 360.1410.

S-(2-cyclopropyl-2-phenyl-2-(pyridin-2-yl)ethyl) benzothioate (3ax)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and (1-cyclopropylvinyl)benzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3ax** (53.9 mg, 75%).


¹H NMR (400 MHz, CDCl₃) δ 8.60 (dd, *J* = 4.8, 1.0 Hz, 1H), δ 7.88 (dd, *J* = 7.2, 1.3 Hz, 2H), 7.56 (td, *J* = 7.8, 1.9 Hz, 1H), 7.52–7.46 (m, 1H), 7.37 (t, *J* = 7.7 Hz, 2H), 7.26 (q, *J* = 1.8 Hz, 4H), 7.20 (ddd, *J* = 12.9, 8.2, 5.3 Hz, 2H), 7.13 (ddd, *J* = 7.4, 4.8, 0.9 Hz, 1H), 4.24 (dd, *J* = 51.2, 12.8 Hz, 2H), 1.69 (tt, *J* = 8.4, 5.7 Hz, 1H), 0.59–0.52 (m, 2H), 0.08 (ddd, *J* = 7.0, 4.7, 2.4 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 189.7, 162.0, 146.4, 141.9, 135.2, 133.3, 130.9, 126.6, 126.3, 125.7, 125.1, 124.5, 122.1, 119.3, 50.8, 37.6, 16.2, 0.0, -0.4.

IR (KBr disc, cm⁻¹): 3078, 3018, 2920, 1657, 1581, 1490, 1475, 1445, 1432, 1348, 1216, 1189, 1162, 1077, 1023, 912, 826, 777, 723, 648, 606, 442, 412.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₃H₂₁NNaOS⁺ 382.1236; Found 382.1232.

S-(2-(pyridin-2-yl)-2-(2-vinylphenyl)ethyl) benzothioate (3ay)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) benzothioate (0.2 mmol) and 1,2-divinylbenzene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ay** (50.4 mg, 73%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 4.2 Hz, 1H), 7.91 (d, *J* = 8.3 Hz, 2H), 7.58–7.47 (m, 2H), 7.39 (dd, *J* = 13.3, 5.1 Hz, 3H), 7.32–7.25 (m, 2H), 7.22–7.09 (m, 3H), 6.68 (dd, *J* = 17.6, 10.9 Hz, 1H), 5.73 (d, *J* = 17.6 Hz, 1H), 5.22 (d, *J* = 10.9 Hz, 1H), 4.41 (dd, *J* = 8.6, 7.0 Hz, 1H), 3.98 (dd, *J* = 13.1, 8.9 Hz, 1H), 3.82 (dd, *J* = 13.2, 6.6 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 192.1, 161.3, 149.3, 142.7, 137.9, 137.1, 136.8, 136.5, 133.3, 128.9, 128.6, 127.6, 127.3, 126.2, 124.8, 123.8, 121.9, 114.1, 52.9, 33.7.

IR (KBr disc, cm⁻¹): 3057, 3006, 2965, 2931, 2350, 1657, 1589, 1581, 1488, 1471, 1432, 1292, 1205, 1175, 1095, 995, 910, 803, 773, 747, 714, 688, 648, 417, 405.

m.p.: 88.2–89.2 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₂H₂₀NOS⁺ 346.1260; Found 346.1263.

***S*-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-methylbenzothioate (3ba)**



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 4-methylbenzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ba** (53.3 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (ddd, *J* = 4.8, 1.7, 0.8 Hz, 1H), 7.84–7.78 (m, 2H), 7.56 (td, *J* = 7.7, 1.8 Hz, 1H), 7.37 (dd, *J* = 8.1, 1.1 Hz, 2H), 7.33–7.27 (m, 2H), 7.23 (dt, *J* = 4.5, 1.8 Hz, 1H), 7.19 (d, *J* = 8.0 Hz, 2H), 7.16 (d, *J* = 7.9 Hz, 1H), 7.13 (ddd, *J* = 7.5, 5.0, 1.2 Hz, 1H), 4.40 (dd, *J* = 8.8, 6.8 Hz, 1H), 3.95 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.80 (dd, *J* = 13.3, 6.7 Hz, 1H), 2.37 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 191.7, 161.5, 149.3, 144.1, 142.5, 136.5, 134.6, 129.2, 128.6, 128.1, 127.3, 127.0, 123.8, 121.8, 53.0, 33.6, 21.7.

IR (KBr disc, cm⁻¹): 3027, 3001, 2923, 2854, 2361, 1950, 1913, 1700, 1642, 1603, 1585, 1493, 1469, 1452, 1430, 1405, 1307, 1270, 1205, 1170, 1148, 1113, 1076, 1036, 993, 909, 840, 814, 790, 746, 717, 697, 643, 627.

m.p.: 73.7–74.6 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₁H₂₀NOS⁺ 334.1260; Found 334.1268.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-methoxybenzothioate (3ca)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 4-methoxybenzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3ca** (60.7 mg, 87%).


¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 4.7 Hz, 1H), 7.90 (d, *J* = 8.8 Hz, 2H), 7.56 (td, *J* = 7.7, 1.6 Hz, 1H), 7.37 (d, *J* = 7.5 Hz, 2H), 7.30 (t, *J* = 7.5 Hz, 2H), 7.24–7.19 (m, 1H), 7.18–7.11 (m, 2H), 6.87 (d, *J* = 8.8 Hz, 2H), 4.40 (dd, *J* = 8.6, 6.9 Hz, 1H), 3.95 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.83 (s, 3H), 3.79 (dd, *J* = 13.3, 6.7 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 190.6, 163.7, 161.6, 149.2, 142.5, 136.5, 130.0, 129.4, 128.6, 128.1, 127.0, 123.8, 121.8, 113.7, 55.5, 53.1, 33.6.

IR (KBr disc, cm⁻¹): 3446, 2975, 2927, 2901, 2361, 2338, 1652, 1599, 1506, 1456, 1310, 1259, 1216, 1166, 1081, 1049, 911, 882, 837, 749, 697, 673, 645, 621, 526, 422.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₁H₂₀NO₂S⁺ 350.1209; Found 350.1201.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-(*tert*-butyl)benzothioate (3da)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 4-(*tert*-butyl)benzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3da** (57.0 mg, 76%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 4.9, 0.8 Hz, 1H), 7.91–7.81 (m, 2H), 7.55 (td, *J* = 7.7, 1.8 Hz, 1H), 7.43–7.35 (m, 4H), 7.30 (dd, *J* = 10.2, 4.8 Hz, 2H), 7.24–7.19 (m, 1H), 7.15 (d, *J* = 7.8 Hz, 1H), 7.12 (ddd, *J* = 7.4, 4.9, 1.0 Hz, 1H), 4.40 (dd, *J* = 8.8, 6.8 Hz, 1H), 3.96 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.80 (dd, *J* = 13.3, 6.7 Hz, 1H), 1.30 (s, 9H).


¹³C NMR (101 MHz, CDCl₃) δ 191.7, 161.6, 157.1, 149.3, 142.5, 136.5, 134.5, 128.6, 128.1, 127.2, 127.0, 125.5, 123.8, 121.8, 53.0, 35.1, 33.7, 31.1.

IR (KBr disc, cm⁻¹): 2962, 2924, 2361, 2341, 1655, 1588, 1473, 1432, 1413, 1261, 1204, 1091, 1018, 908, 795, 762, 689, 649, 614, 567, 416.

m.p.: 97.1–99.3 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₄H₂₆NOS⁺ 376.1730; Found 376.1663.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-fluorobenzothioate (3ea)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 4-fluorobenzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ea** (50.5 mg, 75%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.97–7.89 (m, 2H), 7.56 (td, *J* = 7.7, 1.8 Hz, 1H), 7.40–7.34 (m, 2H), 7.30 (t, *J* = 7.5 Hz, 2H), 7.25–7.19 (m, 1H), 7.13 (ddd, *J* = 7.9, 5.9, 4.3 Hz, 2H), 7.10–7.03 (m, 2H), 4.40 (dd, *J* = 8.9, 6.7 Hz, 1H), 3.98 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.81 (dd, *J* = 13.3, 6.7 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 190.6, 165.9 (d, ¹J_{C-F} = 254.7 Hz), 161.4, 149.3, 142.4, 136.5, 133.5 (d, ⁴J_{C-F} = 2.9 Hz), 129.8 (d, ³J_{C-F} = 9.4 Hz), 128.7, 128.1, 127.1, 123.8, 121.8, 115.7 (d, ²J_{C-F} = 22.0 Hz), 77.4, 77.1, 76.8, 52.9, 33.8.

¹⁹F NMR (376 MHz, CDCl₃) δ -104.89.

IR (KBr disc, cm⁻¹): 3299, 2976, 2930, 2898, 2410, 2361, 2337, 2257, 2133, 1922, 1658, 1596, 1500, 1432, 1408, 1297, 1204, 1155, 1085, 1048, 919, 844, 806, 750, 729, 699, 642, 620, 520, 436. **m.p.:** 67.4–68.0 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇FNOS⁺ 338.1009; Found 338.1035.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-chlorobenzothioate (3fa)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 4-chlorobenzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3fa** (60.7 mg, 86%).

¹H NMR (400 MHz, CDCl₃) δ 8.61 (ddd, *J* = 4.8, 1.6, 0.8 Hz, 1H), 7.88–7.80 (m, 2H), 7.55 (td, *J* = 7.7, 1.8 Hz, 1H), 7.39–7.33 (m, 4H), 7.33–7.26 (m, 2H), 7.24–7.19 (m, 1H), 7.17–7.10 (m, 2H), 4.40 (dd, *J* = 8.8, 6.7 Hz, 1H), 3.98 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.81 (dd, *J* = 13.3, 6.7 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 190.91, 161.3, 149.3, 142.3, 139.7, 136.5, 135.4, 128.8, 128.7, 128.6, 128.1, 127.1, 123.8, 121.9, 52.9, 33.8.

IR (KBr disc, cm⁻¹): 3061, 3006, 2930, 2361, 2337, 1736, 1663, 1587, 1488, 1431, 1396, 1204, 1171, 1090, 915, 835, 749, 698, 641, 580, 532, 475.

m.p.: 67.4–68.5 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇ClNOS⁺ 354.0714; Found 354.0702.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-bromobenzothioate (3ga)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 4-bromobenzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ga** (52.4 mg, 66%).

¹H NMR (400 MHz, CDCl₃) δ 8.61 (ddd, *J* = 4.8, 1.6, 0.8 Hz, 1H), 7.79–7.73 (m, 2H), 7.57–7.49 (m, 3H), 7.37 (dd, *J* = 5.1, 3.5 Hz, 2H), 7.33–7.26 (m, 2H), 7.24–7.18 (m, 1H), 7.12 (ddd, *J* = 7.9, 5.9, 4.4 Hz, 2H), 4.39 (dd, *J* = 8.9, 6.7 Hz, 1H), 3.98 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.82 (dd, *J* = 13.3, 6.7 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 191.1, 161.3, 149.3, 142.4, 136.5, 135.9, 131.8, 128.7, 128.3, 128.1, 127.1, 123.8, 121.9, 52.9, 33.8.

IR (KBr disc, cm⁻¹): 3060, 3026, 2922, 2850, 2361, 1653, 1581, 1568, 1452, 1432, 1415, 1395, 1275, 1203, 1168, 1067, 1010, 993, 912, 829, 747, 718, 697, 638, 589, 439, 416.

m.p.: 72.9–74.4 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇BrNOS⁺ 398.0209; Found 398.0223.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-iodobenzothioate (3ha)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 4-iodobenzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ha** (45.4 mg, 51%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (ddd, *J* = 4.8, 1.6, 1.0 Hz, 1H), 7.79–7.74 (m, 2H), 7.64–7.60 (m, 2H), 7.57 (td, *J* = 7.7, 1.8 Hz, 1H), 7.36 (dd, *J* = 8.2, 1.2 Hz, 2H), 7.33–7.27 (m, 2H), 7.25–7.19 (m, 1H), 7.17–7.11 (m, 2H), 4.39 (dd, *J* = 8.9, 6.7 Hz, 1H), 3.97 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.81 (dd, *J* = 13.3, 6.7 Hz, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 191.4, 161.3, 149.24, 142.3, 137.8, 136.5, 136.4, 128.7, 128.6, 128.1, 127.1, 123.8, 121.9, 101.0, 52.9, 33.8.

IR (KBr disc, cm⁻¹): 3393, 3184, 3054, 2920, 2850, 2360, 1956, 1729, 1652, 1580, 1491, 1470, 1453, 1427, 1388, 1274, 1203, 1174, 1147, 1121, 1076, 1054, 1033, 1002, 908, 819, 799, 746, 695, 637.

m.p.: 111.2–111.8 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇INOS⁺ 446.0070; Found 446.0067.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-(trifluoromethyl)benzothioate (3ia)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 4-(trifluoromethyl)benzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ia** (41.0 mg, 53%).

¹H NMR (400 MHz, CDCl₃) δ 8.63 (dd, *J* = 5.4, 1.4 Hz, 1H), 8.01 (d, *J* = 8.2 Hz, 2H), 7.67 (d, *J* = 8.3 Hz, 2H), 7.58 (td, *J* = 7.7, 1.7 Hz, 1H), 7.37 (d, *J* = 7.3 Hz, 2H), 7.31 (t, *J* = 7.5 Hz, 2H), 7.23 (t, *J* = 7.2 Hz, 1H), 7.16 (dd, *J* = 7.5, 4.2 Hz, 2H), 4.41 (dd, *J* = 8.8, 6.8 Hz, 1H), 4.01 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.85 (dd, *J* = 13.3, 6.7 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 191.2, 161.2, 149.3, 142.2, 139.9, 136.5, 134.6 (q, ²*J*_{C-F} = 32.6 Hz), 128.7, 128.1, 127.6, 127.1, 125.6 (q, ³*J*_{C-F} = 3.7 Hz), 123.8, 123.5 (q, ¹*J*_{C-F} = 272.7 Hz), 121.9, 77.4, 77.0, 76.7, 52.8, 33.9.


¹⁹F NMR (377 MHz, CDCl₃) δ -63.11.

IR (KBr disc, cm⁻¹): 3672, 2971, 2927, 2361, 2337, 1656, 1540, 1514, 1473, 1433, 1402, 1322, 1228, 1174, 1131, 1066, 1017, 921, 850, 775, 748, 698, 653, 619, 473, 422.

m.p.: 55.2–56.4 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₅H₉F₃NO⁺ 388.0977; Found 388.0956.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 3-fluorobenzothioate (3ja)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 3-fluorobenzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ja** (47.9 mg, 71%).

¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 4.2 Hz, 1H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.62–7.57 (m, 1H), 7.54 (td, *J* = 7.7, 1.8 Hz, 1H), 7.35 (dd, *J* = 11.2, 5.0 Hz, 3H), 7.30 (t, *J* = 7.5 Hz, 2H), 7.21 (ddd, *J* = 10.7, 7.5, 2.4 Hz, 2H), 7.17–7.09 (m, 2H), 4.40 (dd, *J* = 8.8, 6.8 Hz, 1H), 3.99 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.83 (dd, *J* = 13.3, 6.7 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 189.8 (d, ⁴*J*_{C-F} = 2.6 Hz), 161.6 (d, ¹*J*_{C-F} = 248.3 Hz), 160.3, 148.2, 141.3, 138.1 (d, ³*J*_{C-F} = 6.6 Hz), 135.4, 129.1 (d, ³*J*_{C-F} = 7.8 Hz), 127.6, 127.0, 126.0, 122.7, 122.0


(d, $^4J_{C-F} = 3.1$ Hz), 120.8, 119.1 (d, $^2J_{C-F} = 21.3$ Hz), 113.0 (d, $^2J_{C-F} = 23.1$ Hz), 51.8, 32.8. ^{19}F NMR (377 MHz, CDCl₃) δ -111.69.

IR (KBr disc, cm⁻¹): 3853, 3742, 3061, 2929, 2359, 1658, 1580, 1466, 1430, 1302, 1204, 1174, 1086, 995, 909, 760, 687, 645.

m.p.: 73.4–74.4 °C.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₁₇FNOS⁺ 338.1009; Found 338.1022.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 3,4-dimethoxybenzothioate (3ka)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 3,4-dimethoxybenzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3ka** (48.5 mg, 64%).


¹H NMR (400 MHz, CDCl₃) δ 8.62 (dd, *J* = 4.7, 0.6 Hz, 1H), 7.59 (dd, *J* = 8.5, 2.1 Hz, 1H), 7.58–7.52 (m, 1H), 7.44 (d, *J* = 2.0 Hz, 1H), 7.40–7.35 (m, 2H), 7.30 (t, *J* = 7.5 Hz, 2H), 7.24–7.19 (m, 1H), 7.16 (d, *J* = 7.8 Hz, 1H), 7.15–7.10 (m, 1H), 6.82 (d, *J* = 8.5 Hz, 1H), 4.41 (dd, *J* = 8.8, 6.7 Hz, 1H), 3.96 (dd, *J* = 13.3, 8.9 Hz, 1H), 3.90 (s, 3H), 3.90 (s, 3H), 3.80 (dd, *J* = 13.3, 6.6 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 190.8, 161.5, 153.4, 149.3, 148.9, 142.6, 136.5, 130.1, 128.6, 128.1, 127.0, 123.8, 121.8, 121.7, 110.2, 109.5, 56.1, 56.0, 53.1, 33.8.

IR (KBr disc, cm⁻¹): 3004, 2959, 2934, 2867, 2837, 2610, 1652, 1584, 1512, 1453, 1433, 1413, 1340, 1262, 1195, 1160, 1139, 1021, 990, 965, 911, 873, 847, 811, 761, 730, 699, 658, 646, 624, 602, 533, 443, 414.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₂H₂₂NO₃S⁺ 380.1315; Found 380.1316.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) naphthalene-2-carbothioate (3la)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) naphthalene-2-carbothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3la** (39.1 mg, 53%).


¹H NMR (400 MHz, CDCl₃) δ 8.64 (dd, *J* = 4.9, 0.8 Hz, 1H), 8.47 (s, 1H), 7.95 (dd, *J* = 8.6, 1.8 Hz, 1H), 7.90 (d, *J* = 8.1 Hz, 1H), 7.83 (d, *J* = 8.6 Hz, 2H), 7.60–7.48 (m, 3H), 7.43–7.37 (m, 2H),

7.32 (t, $J = 7.5$ Hz, 2H), 7.23 (ddd, $J = 8.7, 4.5, 1.3$ Hz, 1H), 7.18 (d, $J = 7.8$ Hz, 1H), 7.16–7.12 (m, 1H), 4.46 (dd, $J = 8.8, 6.8$ Hz, 1H), 4.03 (dd, $J = 13.3, 8.9$ Hz, 1H), 3.88 (dd, $J = 13.3, 6.7$ Hz, 1H).
 ^{13}C NMR (101 MHz, CDCl_3) δ 192.0, 161.5, 149.3, 142.5, 136.5, 135.7, 134.4, 132.4, 129.6, 128.7, 128.7, 128.4, 128.4, 128.1, 127.8, 127.1, 126.9, 123.8, 123.2, 121.8, 53.0, 33.9.

IR (KBr disc, cm^{-1}): 3083, 3059, 2990, 2920, 2850, 1642, 1602, 1569, 1492, 1467, 1433, 1416, 1350, 1276, 1254, 1222, 1173, 1148, 1120, 964, 908, 869, 832, 750, 690, 642, 458, 432, 419, 403.
m.p.: 126.0–127.1 °C.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{24}\text{H}_{20}\text{NOS}^+$ 370.1260; Found 370.1238.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) furan-2-carbothioate (3ma)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) furan-2-carbothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3ma** (37.1 mg, 60%).


^1H NMR (400 MHz, CDCl_3) δ 8.61 (dd, $J = 4.8, 0.7$ Hz, 1H), 7.56 (td, $J = 7.7, 1.8$ Hz, 1H), 7.53–7.50 (m, 1H), 7.36 (d, $J = 7.3$ Hz, 2H), 7.30 (t, $J = 7.5$ Hz, 2H), 7.22 (t, $J = 7.2$ Hz, 1H), 7.18–7.10 (m, 3H), 6.48 (dd, $J = 3.6, 1.7$ Hz, 1H), 4.39 (dd, $J = 8.9, 6.7$ Hz, 1H), 3.94 (dd, $J = 13.3, 9.0$ Hz, 1H), 3.80 (dd, $J = 13.3, 6.6$ Hz, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 180.7, 161.3, 150.9, 149.2, 146.1, 142.4, 136.5, 128.7, 128.1, 127.1, 123.8, 121.8, 115.5, 112.2, 53.0, 32.8.

IR (KBr disc, cm^{-1}): 3674, 2983, 2923, 2361, 1717, 1647, 1586, 1562, 1465, 1431, 1382, 1249, 1150, 1074, 1013, 953, 847, 751, 696, 594, 532, 420.

QTOF-MS: m/z [M + Na]⁺ Calcd for $\text{C}_{18}\text{H}_{15}\text{NNaO}_2\text{S}^+$ 332.0716; Found 332.0713.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) thiophene-2-carbothioate (3na)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) thiophene-2-carbothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3na** (41.0 mg, 64%).

^1H NMR (400 MHz, CDCl_3) 8.62 (d, $J = 4.1$ Hz, 1H), 7.71 (dd, $J = 3.8, 1.0$ Hz, 1H), 7.58–7.53 (m, 2H), 7.36 (d, $J = 7.5$ Hz, 2H), 7.30 (t, $J = 7.5$ Hz, 2H), 7.21 (t, $J = 7.2$ Hz, 1H), 7.18–7.10 (m, 2H),

7.04 (dd, $J = 4.8, 3.9$ Hz, 1H), 4.42 (dd, $J = 8.9, 6.6$ Hz, 1H), 3.96 (dd, $J = 13.3, 9.0$ Hz, 1H), 3.81 (dd, $J = 13.3, 6.6$ Hz, 1H).


^{13}C NMR (101 MHz, CDCl_3) δ 184.2, 161.3, 149.2, 142.4, 142.2, 136.5, 132.6, 131.1, 128.7, 128.1, 127.8, 127.1, 123.9, 121.8, 53.0, 33.8.

IR (KBr disc, cm^{-1}): 3612, 2984, 2904, 2361, 2337, 1650, 1541, 1513, 1410, 1229, 1204, 1072, 1051, 895, 816, 696, 421.

m.p.: 77.8–78.4 °C.

QTOF-MS: m/z [M + Na]⁺ Calcd for $\text{C}_{18}\text{H}_{15}\text{NNaOS}_2^+$ 348.0487; Found 348.0508.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) butanethioate (3oa)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) butanethioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3oa** (49.6 mg, 87%).


^1H NMR (400 MHz, CDCl_3) δ 8.59 (ddd, $J = 4.8, 1.6, 0.8$ Hz, 1H), 7.55 (td, $J = 7.7, 1.8$ Hz, 1H), 7.35–7.24 (m, 4H), 7.23–7.17 (m, 1H), 7.12 (ddd, $J = 5.9, 4.9, 2.4$ Hz, 2H), 4.28 (dd, $J = 8.7, 7.0$ Hz, 1H), 3.76 (dd, $J = 13.3, 8.8$ Hz, 1H), 3.63 (dd, $J = 13.3, 6.9$ Hz, 1H), 2.51–2.42 (m, 2H), 1.71–1.57 (m, 2H), 0.89 (t, $J = 7.4$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 199.5, 161.5, 149.2, 142.3, 136.5, 128.6, 128.1, 127.0, 123.6, 121.8, 53.0, 45.9, 33.5, 19.2, 13.5.

IR (KBr disc, cm^{-1}): 3006, 2964, 2933, 2874, 1683, 1589, 1569, 1493, 1472, 1453, 1433, 1381, 1292, 1274, 1222, 1145, 1114, 1051, 994, 886, 797, 752, 698, 617, 597, 538, 414.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{17}\text{H}_{20}\text{NOS}^+$ 286.1260; Found 286.1255.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) 2,2-dimethylpropanethioate (3pa)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) 2,2-dimethylpropanethioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3pa** (32.3 mg, 54%).


¹H NMR (400 MHz, CDCl₃) δ 8.60 (ddd, *J* = 4.8, 1.7, 0.9 Hz, 1H), 7.60–7.52 (m, 1H), 7.30 (ddd, *J* = 15.5, 8.5, 4.2 Hz, 4H), 7.21 (d, *J* = 7.1 Hz, 1H), 7.14 (dd, *J* = 7.6, 2.5 Hz, 2H), 4.26 (s, 1H), 3.74 (dd, *J* = 13.4, 8.7 Hz, 1H), 3.57 (dd, *J* = 13.4, 6.9 Hz, 1H), 1.17 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 206.9, 161.7, 149.2, 142.4, 136.4, 128.5, 128.1, 126.9, 123.6, 121.7, 53.0, 46.4, 33.3, 27.4.

IR (KBr disc, cm⁻¹): 3004, 2959, 2934, 2867, 1642, 1602, 1569, 1492, 1467, 1433, 965, 911, 873, 847, 811, 761, 730, 699, 658, 646, 624, 602, 533, 443, 414.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₈H₂₂NOS⁺ 300.1417; Found 300.1398.

S-(2-(6-methylpyridin-2-yl)-2-phenylethyl) benzothioate (3qa)



Following the General Procedure with the corresponding *S*-(6-methylpyridin-2-yl) benzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3qa** (56.6 mg, 85%).

¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 7.1 Hz, 2H), 7.53 (t, *J* = 7.4 Hz, 1H), 7.45 (d, *J* = 7.7 Hz, 1H), 7.43–7.36 (m, 4H), 7.30 (t, *J* = 7.5 Hz, 2H), 7.21 (t, *J* = 7.3 Hz, 1H), 6.96 (dd, *J* = 16.0, 7.7 Hz, 2H), 4.36 (dd, *J* = 8.5, 7.1 Hz, 1H), 3.97 (dd, *J* = 13.2, 8.7 Hz, 1H), 3.81 (dd, *J* = 13.2, 6.9 Hz, 1H), 2.57 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 192.2, 160.7, 157.9, 142.6, 137.2, 136.5, 133.2, 128.5, 128.2, 127.2, 126.9, 121.2, 120.3, 52.9, 33.9, 24.7.

IR (KBr disc, cm⁻¹): 3360, 2979, 2902, 2360, 2335, 1657, 1588, 1513, 1432, 1399, 1205, 1049, 906, 883, 818, 748, 721, 687, 490, 452, 421.

m.p.: 84.6–85.1 °C.

QTOF-MS: *m/z* [M + Na]⁺ Calcd for C₂₁H₁₉NNaOS⁺ 356.1080; Found 356.1085.

S-(2-(5-bromopyridin-2-yl)-2-phenylethyl) benzothioate (3ra)



Following the General Procedure with the corresponding *S*-(5-bromopyridin-2-yl) benzothioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the white solid **3ra** (57.3 mg, 72%).

¹H NMR (400 MHz, CDCl₃) δ 8.67 (s, 1H), 7.91 (d, *J* = 7.5 Hz, 2H), 7.67 (dt, *J* = 8.3, 2.3 Hz, 1H), 7.57–7.48 (m, 1H), 7.40 (t, *J* = 6.8 Hz, 2H), 7.37–7.26 (m, 4H), 7.26–7.18 (m, 1H), 7.05 (dd, *J* =

8.3, 1.6 Hz, 1H), 4.37 (dd, J = 11.1, 4.2 Hz, 1H), 3.92 (ddd, J = 13.1, 9.1, 2.2 Hz, 1H), 3.78 (ddd, J = 13.4, 6.4, 2.2 Hz, 1H).


^{13}C NMR (101 MHz, CDCl_3) δ 191.9, 160.1, 150.3, 142.0, 139.1, 137.0, 133.4, 128.8, 128.6, 128.0, 127.3, 125.1, 118.9, 52.5, 33.6.

IR (KBr disc, cm^{-1}): 3059, 3030, 2926, 2853, 2169, 1898, 1819, 1659, 1579, 1459, 1371, 1308, 1206, 1094, 1005, 913, 830, 771, 736, 691, 647.

m.p.: 110.8–111.9 °C.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{20}\text{H}_{17}\text{BrNOS}^+$ 398.0209; Found 398.0208.

S-(2-phenyl-2-(pyridin-2-yl)ethyl) (2*R*)-2-(4-isobutylphenyl)propanethioate (3sa)



Following the General Procedure with the corresponding *S*-(pyridin-2-yl) (*R*)-2-(4-isobutylphenyl)propanethioate (0.2 mmol) and styrene (0.6 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **3sa** (48.4 mg, 60%).


^1H NMR (400 MHz, CDCl_3) δ 8.54 (d, J = 4.0 Hz, 1H), 7.48 (dtd, J = 11.7, 7.7, 1.8 Hz, 1H), 7.30–7.21 (m, 4H), 7.21–7.10 (m, 3H), 7.10–6.98 (m, 4H), 4.22 (dd, J = 16.1, 8.9 Hz, 1H), 3.84–3.75 (m, 1H), 3.75–3.67 (m, 1H), 3.56 (ddd, J = 13.4, 6.9, 2.7 Hz, 1H), 2.44 (d, J = 7.2 Hz, 2H), 1.83 (td, J = 13.5, 6.7 Hz, 1H), 1.46 (d, J = 7.1 Hz, 3H), 0.94–0.83 (m, 6H).

^{13}C NMR (101 MHz, CDCl_3) δ 201.2, 161.5, 161.5, 149.2, 149.2, 142.4, 142.3, 140.8, 140.8, 137.1, 137.1, 136.4, 136.3, 129.4, 129.3, 128.5, 128.1, 127.6, 126.9, 123.6, 123.6, 121.7, 53.9, 53.8, 52.9, 52.8, 45.1, 33.8, 33.8, 30.2, 22.4, 18.5, 18.4.

IR (KBr disc, cm^{-1}): 2954, 2929, 2868, 2350, 1680, 1589, 1569, 1511, 1493, 1469, 1453, 1433, 1383, 1367, 1276, 1022, 996, 946, 847, 801, 750, 698, 617, 545, 466, 441, 416.

QTOF-MS: m/z [M + H]⁺ Calcd for $\text{C}_{26}\text{H}_{30}\text{NOS}^+$ 404.2043; Found 404.2040.

2-(1-phenyl-2-(phenylthio)ethyl)pyridine (4aa)



Following the General Procedure D with the corresponding *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) benzothioate (0.2 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **4aa** (49.5 mg, 85%).


¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 4.6 Hz, 1H), 7.52 (td, *J* = 7.7, 1.9 Hz, 1H), 7.31 (ddd, *J* = 11.5, 6.7, 3.5 Hz, 6H), 7.27 – 7.22 (m, 2H), 7.20 (t, *J* = 7.1 Hz, 1H), 7.15 (t, *J* = 7.3 Hz, 1H), 7.09 (t, *J* = 7.1 Hz, 2H), 4.29 (dd, *J* = 8.2, 7.1 Hz, 1H), 3.95 (dd, *J* = 12.9, 8.4 Hz, 1H), 3.57 (dd, *J* = 12.9, 6.8 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 161.7, 149.4, 142.4, 136.7, 136.4, 129.5, 128.9, 128.6, 128.1, 127.0, 126.0, 123.6, 121.8, 52.9, 38.8.

IR (KBr disc, cm⁻¹): 3058, 3026, 2926, 2350, 1587, 1570, 1493, 1472, 1433, 1331, 1291, 1273, 1197, 1088, 1072, 1052, 1026, 995, 911, 797, 739, 695, 642, 616, 595, 542, 465, 420.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₉H₁₈NS⁺ 292.1154; Found 292.1150.

2-(2-((4-(*tert*-butyl)phenyl)thio)-1-phenylethyl)pyridine (**4da**)



Following the General Procedure D with the corresponding *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-(*tert*-butyl)benzothioate (0.2 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **4da** (50.0 mg, 72%).


¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, *J* = 3.8 Hz, 1H), 7.53 (t, *J* = 7.3 Hz, 1H), 7.37–7.22 (m, 8H), 7.22–7.15 (m, 1H), 7.09 (dd, *J* = 15.3, 7.3 Hz, 2H), 4.30 (t, *J* = 7.5 Hz, 1H), 3.92 (dd, *J* = 12.7, 8.6 Hz, 1H), 3.54 (dd, *J* = 12.8, 6.7 Hz, 1H), 1.29 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 161.8, 149.4, 149.3, 142.5, 136.4, 132.9, 129.8, 128.6, 128.1, 126.9, 126.0, 123.6, 121.7, 53.1, 39.3, 34.5, 31.3.

IR (KBr disc, cm⁻¹): 2961, 2338, 1589, 1570, 1493, 1453, 1433, 1394, 1363, 1340, 1269, 1120, 1012, 924, 820, 743, 698, 617, 576, 491, 468, 458, 449, 431, 426, 420, 413, 402.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₃H₂₆NS⁺ 348.1780; Found 348.1781.

2-(2-(phenylthio)-1-(*p*-tolyl)ethyl)pyridine (**4ab**)



Following the General Procedure D with the corresponding *S*-(2-(pyridin-2-yl)-2-(*p*-tolyl)ethyl) benzothioate (0.2 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **4ab** (47.6 mg, 78%).


¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 4.6 Hz, 1H), 7.53 (t, *J* = 7.6 Hz, 1H), 7.31 (d, *J* = 7.2 Hz, 2H), 7.28–7.19 (m, 4H), 7.18–7.12 (m, 1H), 7.10 (d, *J* = 7.4 Hz, 4H), 4.26 (t, *J* = 7.5 Hz, 1H), 3.92 (ddd, *J* = 12.7, 8.3, 1.5 Hz, 1H), 3.56 (ddd, *J* = 12.8, 7.0, 1.5 Hz, 1H), 2.29 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 161.9, 149.4, 139.4, 136.7, 136.6, 136.4, 129.4, 129.4, 128.9, 127.9, 125.9, 123.5, 121.7, 52.5, 38.8, 21.1.

IR (KBr disc, cm⁻¹): 3073, 3005, 2921, 2327, 1587, 1570, 1512, 1471, 1434, 1290, 1272, 1146, 1110, 1025, 995, 923, 820, 790, 738, 691, 558, 466, 443.

QTOF-MS: *m/z* [M + H]⁺ Calcd for C₂₀H₂₀NS⁺ 306.1311; Found 306.1308.

2-(1-(4-bromophenyl)-2-(phenylthio)ethyl)pyridine (4ag)



Following the General Procedure D with the corresponding *S*-(2-(4-bromophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (0.2 mmol). The crude product was purified by preparative TLC, using PE and EA (v/v = 50/1) as an eluent, to yield the transparent oil **4ag** (42.8 mg, 58%).

¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 4.3 Hz, 1H), 7.56 (td, *J* = 7.7, 1.8 Hz, 1H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.30 (d, *J* = 7.2 Hz, 2H), 7.26 (t, *J* = 7.5 Hz, 2H), 7.21 (d, *J* = 8.4 Hz, 2H), 7.19 – 7.15 (m, 1H), 7.12 (dd, *J* = 7.0, 5.3 Hz, 1H), 7.08 (d, *J* = 7.8 Hz, 1H), 4.22 (t, *J* = 7.6 Hz, 1H), 3.89 (dd, *J* = 13.0, 8.0 Hz, 1H), 3.53 (dd, *J* = 13.0, 7.3 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 161.1, 149.5, 141.3, 136.5, 136.2, 131.7, 129.9, 129.7, 128.9, 126.2, 123.5, 121.9, 120.9, 52.3, 38.8.

IR (KBr disc, cm⁻¹): 3057, 3006, 2958, 2924, 2350, 1586, 1570, 1481, 1470, 1434, 1406, 1203, 1183, 1146, 1090, 1052, 1025, 1010, 996, 822, 789, 738, 712, 690, 650, 540, 457, 435, 419, 404.


QTOF-MS: *m/z* [M + H]⁺ Calcd for C₁₉H₁₇BrNS⁺ 370.0260; Found 370.0252.

References

- S1 S. Riese, M. Holzapfel, A. Schmiedel, I. Gert, D. Schmidt, F. Würthner and C. Lambert, Photoinduced dynamics of bis-dipyrrinato-palladium(II) and porphodimethenato-palladium(II) complexes: Governing near infrared phosphorescence by structural restriction, *Inorg. Chem.*, 2018, **57**, 12480–12488.
- S2 F. H. Lutter, L. Grokenberger, M. S. Hofmayer and P. Knochel, Cobalt-catalyzed acylation-reactions of (hetero)arylzinc pivalates with thiopyridyl ester derivatives. *Chem. Sci.*, 2019, **10**, 8241–8245.
- S3 S. H. H. Zaidi, K. Muthukumaran, S.-i. Tamaru and J. S. Lindsey, 9-Acylation of 1-acyldipyrromethanes containing a dialkylboron mask for the α -acylpyrrole motif, *J. Org. Chem.*, 2004, **69**, 8356–8365.
- S4 P. D. Rao, S. Dhanalekshmi, B. J. Littler and J. S. Lindsey, Rational syntheses of porphyrins bearing up to four different meso substituents, *J. Org. Chem.*, 2000, **65**, 7323–7344.
- S5 M. Ociepa, O. Baka, J. Narodowiec and D. Gryko, Light-driven vitamin B₁₂-catalysed generation of acyl radicals from 2-S-pyridyl thioesters, *Adv. Synth. Catal.*, 2017, **359**, 3560–3565.
- S6 N. Scardovi, P. P. Garner, J. D. Protasiewicz, *S*-(2-Pyridinyl)-1,1,3,3-tetramethylthiouronium hexafluorophosphate. A new reagent for the synthesis of 2-pyridinethiol esters, *Org. Lett.*, 2003, **5**, 1633–1635.
- S7 T. Kitagawa, H. Kuroda, K. Iida, M. Ito and M. Nakamura, Convenient synthesis of amides, esters, and thioesters using 2,2'-oxalyldi(2,3-dihydro-3-oxobenzisosulfonazole), *Chem. Pharm. Bull.*, 1989, **37**, 3225–3228.
- S8 S. KC, R. K. Dhungana, B. Shrestha, S. Thapa, N. Khanal, P. Basnet, R. W. Lebrun and R. Giri, Ni-catalyzed regioselective alkylarylation of vinylarenes via C(sp³)–C(sp³)/C(sp³)–C(sp²) bond formation and mechanistic studies, *J. Am. Chem. Soc.*, 2018, **140**, 9801–9805.
- S9 G. M. Sheldrick, Crystal structure refinement with SHELXL, *Acta Crys.* 2015, **C71**, 3–8.

NMR Spectra

Fig. S16. The ^1H (400 MHz), ^{13}C (101 MHz) and ^{19}F (377 MHz) NMR spectra for *S*-(pyridin-2-yl) 4-fluorobenzothioate (**1e**) in CDCl_3







Fig. S17. The ^1H (400 MHz), ^{13}C (101 MHz) and ^{19}F (377 MHz) NMR spectra for *S*-(pyridin-2-yl) 3-fluorobenzothioate (**1j**) in CDCl_3






Fig. S18. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(pyridin-2-yl) 3,4-dimethoxybenzothioate (**1k**) in CDCl_3




Fig. S19. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(6-methylpyridin-2-yl)benzothioate (**1q**) in CDCl_3




Fig. S20. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(5-bromopyridin-2-yl)benzothioate (**1r**) in CDCl_3




Fig. S21. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(6-methylpyridin-2-yl) 4-methylbenzothioate (**1t**) in CDCl_3




Fig. S22. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 4-vinylbenzyl (*R*)-2-(4-isobutylphenyl)propanoate (**2u**) in CDCl_3




Fig. S23. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 4-vinylbenzyl (*S*)-2-(6-methoxynaphthalen-2-yl)propanoate (**2v**) in CDCl_3




Fig. S24. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)benzothioate (**3aa**) in CDCl_3




Fig. S25. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(pyridin-2-yl)-2-(*p*-tolyl)ethyl) benzothioate (**3ab**) in CDCl_3




Fig. S26. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(4-(*tert*-butyl)phenyl)-2-(pyridin-2-yl)ethyl) benzothioate (**3ac**) in CDCl_3




Fig. S27. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(4-methoxyphenyl)-2-(pyridin-2-yl)ethyl) benzothioate (**3ad**) in CDCl_3





Fig. S28. The ^1H (400 MHz), ^{13}C (101 MHz) and ^{19}F (377 MHz) NMR spectra for *S*-(2-(4-fluorophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (**3ae**) in CDCl_3






Fig. S29. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(4-chlorophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (**3af**) in CDCl_3




Fig. S30. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(4-bromophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (**3ag**) in CDCl_3





Fig. S31. The ^1H (400 MHz), ^{13}C (101 MHz) and ^{19}F (377 MHz) NMR spectra for *S*-(2-(pyridin-2-yl)-2-(4-(trifluoromethyl)phenyl)ethyl) benzothioate (**3ah**) in CDCl_3



-62.43





Fig. S32. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)phenyl acetate (**3ai**) in CDCl_3




Fig. S33. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(pyridin-2-yl)-2-(*m*-tolyl)ethyl) benzothioate (**3aj**) in CDCl_3




Fig. S34. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(3-chlorophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (**3ak**) in CDCl_3




Fig. S35. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(2-chlorophenyl)-2-(pyridin-2-yl)ethyl) benzothioate (**3al**) in CDCl_3




Fig. S36. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(naphthalen-2-yl)-2-(pyridin-2-yl)ethyl) benzothioate (**3am**) in CDCl_3




Fig. S37. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2,2-di(pyridin-2-yl)ethyl)benzothioate (**3an**) in CDCl_3




Fig. S38. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)propyl) benzothioate (**3ao**) in CDCl_3




Fig. S39. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2,2-diphenyl-2-(pyridin-2-yl)ethyl) benzothioate (**3ap**) in CDCl_3




Fig. S40. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(1-phenyl-1-(pyridin-2-yl)propan-2-yl) benzothioate (**3aq**) in CDCl_3




Fig. S41. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(3-phenyl-2-(pyridin-2-yl)propyl) benzothioate (**3ar**) in CDCl_3




Fig. S42. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)benzyl 2-(*p*-tolyl)acetate (**3as**) in CDCl_3




Fig. S43. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)benzyl 2-(1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl)acetate (**3at**) in CDCl_3




Fig. S44. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)benzyl (2*R*)-2-(4-isobutylphenyl)propanoate (**3au**) in CDCl_3




Fig. S45. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 4-(2-(benzoylthio)-1-(pyridin-2-yl)ethyl)benzyl (2*S*)-2-(6-methoxynaphthalen-2-yl)propanoate (**3av**) in CDCl_3




Fig. S46. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(1-cyclopropyl-2-phenyl-2-(pyridin-2-yl)ethyl) benzothioate (**3aw**) in CDCl_3




Fig. S47. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-cyclopropyl-2-phenyl-2-(pyridin-2-yl)ethyl) benzothioate (**3ax**) in CDCl_3




Fig. S48. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(pyridin-2-yl)-2-(2-vinylphenyl)ethyl) benzothioate (**3ay**) in CDCl_3




Fig. S49. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)-4-methylbenzothioate (**3ba**) in CDCl_3




Fig. S50. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-methoxybenzothioate (**3ca**) in CDCl_3




Fig. S51. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)-4-(*tert*-butyl)benzothioate (**3da**) in CDCl_3





Fig. S52. The ^1H (400 MHz), ^{13}C (101 MHz) and ^{19}F (377 MHz) spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-fluorobenzothioate (**3ea**) in CDCl_3



-104.89





Fig. S53. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)-4-chlorobenzothioate (**3fa**) in CDCl_3




Fig. S54. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)-4-bromobenzothioate (**3ga**) in CDCl_3




Fig. S55. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)-4-iodobenzothioate (**3ha**) in CDCl_3





Fig. S56. The ^1H (400 MHz), ^{13}C (101 MHz) and ^{19}F (377 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) 4-(trifluoromethyl)benzothioate (**3ia**) in CDCl_3



-63.11






Fig. S57. The ^1H (400 MHz), ^{13}C (101 MHz) and ^{19}F (377 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) 3-fluorobenzothioate (**3ja**) in CDCl_3






Fig. S58. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) 3,4-dimethoxybenzothioate (**3ka**) in CDCl_3




Fig. S59. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)naphthalene-2-carbothioate (**3la**) in CDCl_3




Fig. S60. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)furan-2-carbothioate (**3ma**) in CDCl_3




Fig. S61. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) thiophene-2-carbothioate (**3na**) in CDCl_3




Fig. S62. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl) butanethioate (**3oa**) in CDCl_3




Fig. S63. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)2,2-dimethylpropanethioate (**3pa**) in CDCl_3




Fig. S64. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(6-methylpyridin-2-yl)-2-phenylethyl) benzothioate (**3qa**) in CDCl_3




Fig. S65. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-(5-bromopyridin-2-yl)-2-phenylethyl) benzothioate (**3ra**) in CDCl_3




Fig. S66. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for *S*-(2-phenyl-2-(pyridin-2-yl)ethyl)-(2*R*)-2-(4-isobutylphenyl)propanethioate (**3sa**) in CDCl_3




Fig. S67. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 2-(1-phenyl-2-(phenylthio)ethyl)pyridine (**4aa**) in CDCl_3




Fig. S68. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 2-(2-((4-(*tert*-butyl)phenyl)thio)-1-phenylethyl)pyridine (**4da**) in CDCl_3




Fig. S69. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 2-(2-(phenylthio)-1-(*p*-tolyl)ethyl)pyridine (**4ab**) in CDCl_3




Fig. S70. The ^1H (400 MHz), ^{13}C (101 MHz) NMR spectra for 2-(1-(4-bromophenyl)-2-(phenylthio)ethyl)pyridine (**4ag**) in CDCl_3

